Screening for disease-causing genes in black South African patients with Parkinson’s disease by Ntsapi, Claudia
i 
Screening for disease-causing genes in Black South 
African patients with Parkinson’s Disease 
By 
Claudia Ntsapi 
Supervisor: Associate Professor Soraya Bardien 
Faculty of Medicine and Health Sciences 
Department of Biomedical Sciences 
Co-supervisor: Dr. Sihaam Boolay 
Faculty of Medicine and Health Sciences 
Department of Biomedical Sciences 
March 2015 
ii 
DECLARATION 
I, the undersigned, hereby declare that the entirety of the work contained in this thesis is my own 
original work (save to the extent explicitly otherwise stated) and that I have not previously in its 
entirety or in part submitted it at any university for a degree. 
Signature: …C. Ntsapi……………………………………Date: …………March 2015………………… 
Copyright © 2015 Stellenbosch University 
All rights reserved. 
Stellenbosch University  https://scholar.sun.ac.za
iii 
 
ABSTRACT 
Parkinson's disease (PD) is an increasingly common neurodegenerative disorder involving the 
progressive loss of dopaminergic neurons in the substantia nigra pars compacta, which leads 
to disruption of the motor circuit. Neuronal cell loss in excess of 50% of normal levels is required 
for the development of clinical symptoms, including tremor, muscular rigidity, bradykinesia, 
and postural instability. There is currently no available drug to prevent, reverse, or halt the 
progression of the disease, but limited symptomatic treatment is available. Increasing age is 
considered to be one of the strongest risk factors for PD. As current epidemiological studies 
project that worldwide populations will increase significantly in age, this has important 
implications for PD.  
Although the molecular mechanisms underlying neuronal degeneration leading to PD remains 
unknown, it has becoming increasingly clear that genetic factors (alone or in combination 
with environmental factors), contribute to the complex pathogenesis of the disease. Eight 
validated genes have been directly implicated in the aetiology of PD, namely: parkin, PINK1, 
DJ-1, ATP13A2, SNCA, LRRK2, VPS35, and EIF4G1. These genes have been predominantly 
identified and studied in European, North American and Asian populations; whereas results 
from Sub-Saharan African (SSA) populations, especially those of Black African ancestry remain 
underrepresented in genetic studies. Given the fact that results obtained from other 
populations may not be transferable to SSA populations as well as the projected increase in 
this disorder worldwide, it is crucial that comprehensive genetic studies are performed in 
traditionally understudied populations of SSA.  
To this end, the aim of the present study was to investigate the molecular aetiology of PD in a 
group of Black South African (SA) PD patients. A total of 47 patients were recruited for the 
study, and 26% had a positive family history of the disorder with the average age at onset 
being 55.3 ± 11.2 years. Mutation screening of the known PD genes was performed. 
Additionally, mutation screening of GBA was also performed, as heterozygous mutations in this 
gene serve as the strongest risk factor for PD. A variety of mutation-screening techniques was 
employed, namely: Sanger sequencing and high-resolution melt (for detection of missense 
mutations and small insertions or deletions), and multiplex-ligation dependent probe 
amplification assay (for detection of copy number changes). Furthermore, next generation 
sequencing was used for systematic screening of the known PD genes plus an additional 160 
candidate genes. In addition, genotyping of CAG repeat expansions in the genes encoding 
ataxin-2 (SCA2) and ataxin-7 (SCA7) was performed using fluorescently-labelled polymerase 
chain reaction primers followed by electrophoresis on the ABI 3130xl Genetic Analyzer.  
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Mutation screening revealed that the known PD genes do not play a significant causal role in 
disease pathogenesis in the current group of Black SA patients, as only 2 out of 47 (4.3%) 
patients screened harboured mutations in parkin. One patient had a heterozygous exon 2 
duplication and a heterozygous exon 9 deletion, and another patient had a heterozygous 
exon 4 deletion and a heterozygous G430D mutation. Moreover, a Q311K, change in parkin 
and four novel variants (I610T, H1758P, N2133S, and T2423S) were found in LRRK2, however the 
pathogenicity of these variants needs to be investigated further. None of the patients had 
pathogenic repeat expansions at the SCA2 and SCA7 loci, thereby excluding these two 
spinocerebellar ataxia subtypes as genetic modifiers of PD, or as a cause of the disease 
phenotype in this group of patients. No pathogenic mutations were found in any of the 
remaining known PD genes, it is therefore likely that these patients harbour mutations in novel 
PD-causing genes.  
This is the first molecular genetic study exclusively of Black SA PD patients, and the first 
comprehensive analysis of all the known PD genes in a SSA population. Common pathogenic 
mutations in these genes, previously shown to be disease causing in several European 
populations, were not detected in the present study and can therefore be excluded as the 
cause of PD in this group of patients. However, given the relatively small sample size, further 
mutation screening of a larger cohort could prove beneficial in the elucidation of novel 
disease-causing genes which may potentially refute/substantiate a current hypothesis which 
suggests that the genetic aetiology of PD is distinctly different across various ethnic populations 
groups worldwide. Continued effects to screen this group of patients may shed insight into 
population specific genetic determinants, which may aid in the identification of novel drug 
targets. 
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OPSOMMING 
Parkinson se siekte ( PD ) is 'n toenemend algemene neurodegeneratiewe siekte wat die 
progressiewe verlies van dopaminergiese neurone in die substantia nigra pars compacta 
behels, wat lei tot die ontwrigting van die motororiese senuweestelsel. ’n Neuronale verlies van 
meer as 50% van die normale vlakke is nodig vir die ontwikkeling van die kliniese simptome, 
insluitende bewing, spier rigiditeit, bradykinesia, en posturale onstabiliteit. Alhoewel beskikbare 
medikasies vir PD wel simptome onderdruk, is dit nie in staat om die siekte te voorkom of 
vordering daarvan te verhoed nie. Een van die mees bedeidende risikofaktore vir PD is 
toenemende ouderdom. Huidige epidemiologiese studies voorspel ‘n toename in populasie 
ouderdom wat belangrike implikasies vir die voorkoms van PD kan inhou.  
Die molekulere meganismes onderliggend aan die neurale agteruitgang in PD is steeds 
onbekend, maar dit blyk dat ‘n aantal genetiese faktore (in kombinasie met 
omgewingsfaktore) bydra tot die komplekse patogeniese agteruitgang van die siekte. Agt 
bevestigde gene is gevind om direk betrokke te wees by die etiologie van PD, naamlik: parkin, 
PINK1, DJ-1, ATP13A2, SNCA, LRRK2, VPS35, en EIF4G1. Hierdie gene is oorwegend 
geïdentifiseer en bestudeer in die Europese, Noord-Amerikaanse en Asiatiese bevolkings; 
terwyl die bestudering van Sub -Sahara- Afrika (SSA) bevolkings, veral dié van Swart Afrika 
afkoms, onderverteenwoordig bly in genetiese studies. Siende dat resultate verkry vanaf ander 
bevolkings nie verwant is aan die SSA bevolking nie, en ook nie ‘n voorspelling van wereldwye 
toename van die siekte kan verteenwoordig nie, is dit van belang dat omvattende genetiese 
studies uitgevoer word op hierdie onderbestudeerde bevolkings van SSA. 
Desnieteenstaande, die doel van die studie was om die molekulere etiologie van PD in ‘n 
groep Swart Suid-Afrikaanse (SA) PD pasiente te ondersoek. ‘n Totaal van 47 pasiente is gewerf 
vir die studie waarvan 26% ‘n famielie geskiedenis het vir die afwyking. Die gemiddelde 
ouderdom van aanvang vir die pasiente was 55.3 ± 11.2 jaar. Mutasie volgorderbepaling vir 
alle bekende PD gene is uitgevoer. Addisionele mutasie volgorderbepaling vir die GBA is ook 
uitgevoer siende dat heterosigotiese mutasies in die geen dien as ‘n sterk risikofaktor vir die 
ontwikkeling van PD. ‘n Verskeidenheid mutasie volgordebepalingstegnieke is geinkorporeer 
vir die studie, naamlik: Sanger volgordebepaling en hoë resolusie smelt tegniek (vir die 
identifisering van missense mutasies asook kleinskaalse invoegings of weglatings), en multiplex-
afbinding afhanklike ondersoek versterkingstoets (vir die opsporing van veranderinge in 
kopiegetal). Verder is volgende generasie volgordebepaling gebruik vir die sistematiese 
ondersoek van die bekende PD gene, asook vir 160 kandidaat gene wat vooraf bepaal is. 
Fluoreserend-geetiketeerde polymerase ketting reaksie primers is gebruik vir genotipering van 
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CAG herhalings uitbreidings in die ataxin-2 (SCA2) en die ataxin-7 (SCA7) gene, gevolg deur 
elektroforese met behulp van die “ABI 3130x1 Genetic Analyzer”.  
Mutasie volgordebepaling het voor die lig gebring dat die bekende PD gene klaarblyklik nie 
‘n beduidende oorsaaklike rol speel in die patogenese van die siekte in die huidige groep 
Swart SA pasiente nie, want slegs 2 uit die 47 (43%) pasiente koester mutasies in parkin. Een van 
die pasiente besit ‘n heterosigotiese duplikasie van ekson 2 en ‘n heterosigotiese weglating 
van ekson 9; in die ander pasient is ‘n heterosigotiese ekson 4 weglating en ‘n heterosigotiese 
G430D mutasie geïdentifiseer. Verder is ‘n Q311K verandering in parkin gevind asook vier nuwe 
variante (I610T, H1758P, N2133S en T2423S) in die LRRK2 geen. Die patogenisiteit van hierdie 
variante moet egter nog bepaal word. Geen patogeniese herhaalings uitbreidings is gevind 
in die SCA2 en SCA7 lokusse nie, en die moontlikheid van die twee spinocerebellar ataksie 
subtipes as genetiese bepalers vir PD is uitgekanselleer. Geen patogeniese mutasies is gevind 
in enige van die oorblywende bekende PD gene nie, dit is dus waarskeinlik dat die pasiente 
wel mutasies in nuwe PD-geassosieerde gene besit. 
Hierdie is die eerste molekulere genetiese studie uitgevoer op uitsluitlik Swart SA PD pasiente, 
en ook die eerste omvattende ondersoek van al die bekende PD gene in ‘n SSA bevolking. 
Die algemene patogeniese mutasies in gene, wat voorheen bewys is as siekte veroorsakend 
in ‘n aantal Europese bevolkings, is nie bespeur in die huidige studie nie en kan dus nie 
verantwoordelik gehou word vir die voorkoms van PD in hierdie pasiente nie. Maar, siende dat 
die steekproefgrootte in hierdie studie relatief klein was, kan addisionele volgordebepaling 
van ‘n groter pasient groep voordelig wees in die bepaal van nuwe siekte-veroorsakende 
gene wat die potensiaal het om huidige hipoteses, dat die genetiese etiologie van PD duidelik 
verskil oor verskeie etniese groepe wereldwyd, te weerlê of bevestig. Die voortsetting van 
genetiese ondersoeke onder hierdie groep pasiente kan bydra tot insig met betrekking tot 
bevolking-spesifieke genetiese bepalers, en uiteindelik tot die identifisering van nuwe teikens 
vir medikasies teen die siekte.
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1.1 General introduction 
Parkinson’s disease (PD) was already known for decades in Ayurveda India under the pseudo-
name “Kampavata” before being formally documented in a monograph by Dr. James Parkinson 
in 1817, in which he described six cases of “involuntary tremulous motion with lessened muscular 
power” (Parkinson, 2002; Kempster et al., 2007). Decades passed before his work was finally 
recognized by French neurologist Jean Martin Charcot who named the disorder “la maladie de 
Parkinson” (i.e. Parkinson’s disease) (Camacho and Francisco, 2012). Nearly fifty years passed 
thereafter, before a neurologist by the name of Fritz Heinrich Lewy first described inclusion bodies 
as one of the hallmark features of PD pathology (Holdorff, 2002). Although these inclusion bodies, 
often referred to as Lewy bodies (LBs), are regarded as the pathological hallmark for PD, they are 
not common to all cases nor are they disease-specific, and have been described in a number of 
other conditions including Lewy body dementia (LBD), multiple system atrophy (MSA), 
corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP) (Halliday et al., 2011). 
These other neurodegenerative disorders are often classified as “parkinsonism”, or “Parkinson-plus 
syndromes”, which are clinically characterized by the presence of selective PD features, in 
addition to other symptoms which are not characteristic of the disorder (Nacimiento, 2006). Unless 
stated otherwise, PD in this text refers either to the sporadic/idiopathic form of the disease, which 
has no identifiable environmental or genetic cause, or familial PD, which typically has an 
underlying genetic cause. 
1.1.1 Clinical features and disease pathology of PD 
The four cardinal symptoms of PD relate to motor dysfunction. Clinically, these symptoms manifest 
as resting tremor (initially affects muscle movement on one side of the body at disease onset), 
bradykinesia (i.e. slowness in the initiation of voluntary movement, with progressive reduction in 
speed and amplitude of repetitive actions), rigidity (due to increased contraction of both agonist 
and antagonist muscles), and postural reflex impairment which is more common in stages of the 
disease (Fahn, 2003). Nonmotor symptoms may include depression, sleep disorders, hallucinations 
and delirium (Amar et al., 2014). Psychiatric symptoms, including anxiety and mood disorders, 
have been reported in nearly 40% of PD cases, while autonomic dysfunction (e.g. constipation, 
loss of smell and sleep disorders) are universal to all PD cases (Dissanayaka et al., 2014). Although 
PD symptoms become progressively more debilitating over time, they are not directly fatal, with 
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the most frequent cause of death in the majority of reported cases being pneumonia, sepsis, 
fractures, and falls, respectively (Hely et al., 2008; Pennington et al., 2010). 
The neuropathological hallmark of PD is characterized by the depigmentation of specific 
neuronal populations in the brain, most notably the dopaminergic neurons of the substantia nigra 
pars compacta (SNpc) of the midbrain (Figure 1.1). Dopaminergic neurons are the main source 
of dopamine (DA) neurotransmitter in the central nervous system (CNS), with a prominent role in 
voluntary movement and behavioural processes (Chinta and Andersen, 2005). Dopaminergic cell 
loss in excess of 50% is required to trigger the onset of PD symptoms (Farrer, 2006). Evidence of 
dopaminergic loss is often accompanied by the presence of LBs, which are abnormal 
proteinaceous aggregates (Figure 1.2) enriched in α-synuclein and ubiquitinated proteins 
(Poulopoulos et al., 2012). 
1.1.1.1 The role of dopamine in PD 
DA is an essential neurotransmitter which plays a key role in controlling voluntary movement, 
balance, cognition, and neuroendocrine secretion for the normal functioning of the CNS 
(Salamone and Correa, 2012). Additionally, DA also plays a role in the brain's complex system of 
motivation and reward (Jaber et al., 1996). Consequently, depletion of DA within the SNpc (Figure 
1.3), results in the dysregulation of essential motor circuits, responsible for controlling and 
maintaining voluntary movement (Gancher, 2002). 
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Figure 1.1 Neuropathology of PD. (A and B) Schematic illustration of the impaired nigrostriatal pathway (shown in 
red) in a PD patient compared to a healthy control. The PD SNpc shows prominent loss of dopaminergic neurons 
projecting to the putamen (dashed red line), and a modest loss of those projecting to the caudate (thin red solid 
line). The schematic illustration also demonstrates depigmentation of the SNpc (i.e. loss of dark-brown pigment - 
neuromelanin; as indicated by arrows), due to the excessive loss of dopaminergic neurons [taken from (Dauer and 
Przedborski, 2003)]. The Nigrostriatal pathway is the main circuit in the CNS, involved in the transmission of 
electrochemical signals which facilitate both voluntary and involuntary movement. 
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Figure 1.2 Post-mortem immunohistochemical labelling of LBs in human brain tissue from an individual with PD. 
Protein specific antibodies are used for the detection of α-synuclein and ubiquitin, which form part of LBs [taken 
from (Dauer and Przedborski, 2003)]. 
Figure 1.3 DaTSCAN (dopamine transporter) image showing the uptake of 18F-DOPA (Fluoro-dopa-18) in the brain 
of a healthy volunteer compared to that of an individual with PD. 18F-DOPA is used as a radiotracer which measures 
DA distribution in the basal ganglia (i.e. the brains ‘control centre’, includes the SNpc). The bright orange areas in 
the scan show a robust uptake of fluorodopa, which indicates normal DA distribution and function. Green to blue 
areas are indicative of significantly less fluorodopa uptake, which indicates a considerable loss of DA receptors, as 
observed in PD patients [(taken from (Brooks, 2004)]. 
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1.1.2 Treatment of PD 
There is currently no treatment to prevent, reverse, or halt the process of neurodegeneration in 
PD. Two primarily symptomatic approaches are therefore used in the treatment of the disorder. 
Firstly, a disease modifying approach which slows down disease progression, and secondly, a 
symptomatic treatment approach with the specific aim of alleviating the more debilitating 
symptoms of the disease (Freire and Santos, 2010). Available symptomatic treatments currently 
include medical and surgical options. Anticholinergics are typically used in patients in whom 
tremor is the prominent symptom, but individual drug response is highly variable. Other 
medications include monoamine oxidase inhibitors (MAOIs), catechol-O-methyltransferase 
(COMT) inhibitors, DA agonists, and the more commonly used levodopa (L-DOPA) replacement 
therapy (Warren et al., 2014). Since its first discovery nearly forty-five years ago, L-DOPA remains 
the most effective symptomatic PD drug, and forms the backbone of a variety of other treatment 
options throughout the course of the disease (Barbeau, 1969). L-DOPA alleviates the severity of 
tremor, rigidity, and mildly improves muscle control and overall balance (Freire and Santos, 2010). 
However, as the disease progresses, patients often have to contend with a range of adverse side 
effects as L-DOPA becomes increasingly less effective, with patients often experiencing 
prolonged ‘wearing-off’ periods, characterized by increased motor fluctuations, dyskinesia (i.e. 
uncontrolled spasmodic or repetitive motions), and dystonia (i.e. involuntary muscle contractions) 
(Marsden, 1994; Thanvi and Lo, 2004). Consequently, surgical treatment is considered to be the 
best treatment option for patients with advanced PD, or for whom drug therapy is no longer 
sufficient. Deep brain stimulation (DBS) is the most commonly used surgical treatment, involving 
the implantation of deep-brain electrodes which send electrical impulses to specific parts of the 
brain (Wertheimer et al., 2014). Controlled electrical stimulation of selective regions of the brain 
(e.g. the motor thalamus, or the subthalamic nucleus), is facilitated through the reduction of 
neural activity in the tissues surrounding the surgically implanted electrodes (Freund, 2005). The 
motor thalamus is primarily targeted for the alleviation of tremor; while DBS of the subthalamic 
nucleus is performed for the treatment of bradykinesia, rigidity, and drug-induced dyskinesia 
(Rodriguez-Oroz et al., 2005). Some of the more prominent disadvantages of DBS include the 
exorbitant cost of the procedure and the need for repeated adjustment of the stimulation 
parameters (Obeso et al., 2001). DBS is only recommended for patients with severe motor 
fluctuations which can no longer be controlled by medication, or those who are intolerant to 
medication, as long as they do not have severe cognitive impairment (Bronstein et al., 2011). 
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1.1.3 The incidence and prevalence of PD 
1.1.3.1 Incidence 
Standardized incidence rates for PD, determined from prospective population-based studies, are 
estimated to be 8 to 18/100,000 person-years, with a 1.5% lifetime risk of developing the disease 
(de Rijk et al., 1995). Incidence rates for PD across all age groups are reported to range from 1.5-
22/100,000 person-years, while studies which are solely restricted to older populations (≥ 60 years 
of age) report an overall incidence rate of 529/100,000 person-years, with an estimated 59,000 
new cases reported each year in the United States alone (Hirtz et al., 2007). Variations in PD 
incidence across different ethnic groups may provide clues about the aetiology of the disorder, 
such as differences in environmental exposures, susceptibility alleles, or population specific PD 
causative genes. However, such comparative studies continue to be hampered by differences in 
case ascertainment, sample size, the diagnostic criteria used, methodological restrictions, and 
biased reporting (Brewis et al., 1966; Marttila and Rinne, 1976).  
1.1.3.2 Prevalence 
The prevalence rate of PD in European countries is estimated to be approximately 108 to 
257/100,000 persons per year, but this figure varies from country to country. When only older age 
groups (≥ 60 years) were included in the study, the prevalence rate varied from 1280 to 
1500/100,000 persons per year (von Campenhausen et al., 2005). The prevalence of PD in Asian 
countries is slightly lower, with figures varying from 51.3 to 176.9/100,000 persons per year across all 
age groups (Muangpaisan et al., 2009). However, the prevalence of PD is thought to be even 
lower in African countries, with the crude prevalence varying from 7 to 31.4/100,000 persons per 
year (Okubadejo et al., 2006; Okubadejo, 2008). Moreover, these figures are generally lowest in 
the east and west African countries, where life expectancy is thought to be the lowest (Richards 
and Chaudhuri, 1996). In contrast, PD prevalence rates are comparatively higher in north African 
countries, but still significantly lower than that reported for European countries (McInerney-Leo et 
al., 2004). However, these estimates are often subjective, and vary considerably due to 
differences in population structure, the diagnostic criteria used, and a high percentage of 
underreporting, particularly in African countries which are generally faced with pressing political 
issues and limited access to health care facilities (Bower and Zenebe, 2005; Pearce and Wilson, 
2007). Thus, it is not known whether PD is more common in certain African countries than others, 
what is certain is that the number of persons 60 years and older is increasing worldwide due to the 
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current trend of population aging, which is thought to result in an increased prevalence of age-
related diseases such as PD (Lee and Mason, 2011). This trend has previously been described in 
an analysis by Dorsey et al. (2007), who using published PD prevalence studies from Europe’s five 
most populous countries (Germany, France, the United Kingdom, Italy, and Spain) and the ten 
most populous nations worldwide (China, India, United States, Indonesia, Brazil, Pakistan, 
Bangladesh, Russia, Nigeria, and Japan), estimated that the number of individuals with PD over 
age 50 was between 4.1 and 4.6 million in 2005. By 2030, this number is expected to increase by a 
factor of two, to between 8.7 and 9.3 million people with PD (Dorsey et al., 2007). Results from a 
similar study by Bach et al. (2011) projected a 1.6 fold increase between 2010 and 2035 in the 
number of PD affected individuals over the age of 50 years (Figure 1.4), which is comparable with 
the earlier projections by Dorsey et al. (2007). 
Figure 1.4 Projected increase in the number of individuals over age 50 with PD by country, 2010 through to 2050. 
27 European countries (EU37), the United States of America (USA), Bulgaria (BG), Ireland (IE) and Canada are 
graphically represented [taken from (Bach et al., 2011)]. 
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1.2 The aetiology of PD 
The majority of PD cases are thought to arise due to a combination of environmental factors that 
confer an increased risk for the disease, and genetic factors that may cause or modify disease 
susceptibility. Over the last decade, the aetiology of PD has shifted considerably towards the 
genetic hypothesis following the identification of a growing number of PD-causative genes. An 
estimated 5-10% of PD cases are thought to stem from purely inherited genetic factors, but even 
these cases where there appears to be a deterministic genetic cause, are often complicated by 
incomplete penetrance (Vaughan et al., 1998). Incomplete penetrance is evident either when 
carriers of a disease-causing mutation die before the manifestation of the disease, or if the effect 
of the mutation is not strong enough to manifest the disease phenotype in all carriers. This 
observation is thought to be strong evidence of the existence of a complex gene-to-gene-
interaction, or a gene-environment interaction which may cause an individual to have an 
increased susceptibility to certain PD triggers (Sveinbjörnsdottir et al., 2000). In a classic twin study 
design, concordance rates in monozygotic (i.e. genetically identical) and dizygotic (i.e. share half 
of their genome) twins are compared; if concordance rates are higher in monozygotic twins, 
genetic factors are thought to be the primary cause of a disease. Findings from early twin studies 
showed little concordance in monozygotic twins when PD developed after the age 50 years 
(Ward et al., 1983; Marttila et al., 1988), but complete concordance was reported for disease 
onset before the age of 50 years (Tanner et al., 1999). These findings suggest that genetic factors 
may be responsible for a significant proportion of early-onset cases (≤ 50 years), and less so for 
late-onset PD cases (≥ 60 years).  
1.2.1 Demographic, environmental and lifestyle risk factors for PD 
1.2.1.1 Gender and increasing age 
Increasing age serves as one of the strongest risk factors for the majority of neurodegenerative 
diseases, including PD (Benito-León et al., 2003). Work by Bower et al. (1999) studied the age and 
gender specific incidence of PD in Olmstead County, where they found that the incidence of PD 
in men 60 years and older, to be 50% higher than that reported for women. Van Den Eeden and 
colleagues (2003) reported a similar finding in the Kaiser Permanente population in the mid-1990s. 
They reported an incidence rate of 120 in 100,000 men between 70 and 80 years of age, while an 
incidence rate of 80 in 100,000 was reported for women in the same age bracket.  
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The loss of selective female hormones, as a consequence of increasing age, is also thought to be 
a risk factor for PD. One such example is the loss of estrogen production in elderly women (60 years 
and older). Estrogen is thought to confer a neuroprotective effect, and there is strong evidence 
to suggest that early menopause, a hysterectomy or removal of the ovaries may increase the risk 
for PD (Popat et al., 2005). Studies in a small clinical trial consisting of postmenopausal women with 
PD, showed significant improvement of motor function in patients who received estrogen 
replacement therapy, compared to those who had not (Tsang et. al, 2000). Estrogen is therefore 
thought to confer a neuroprotective role against PD, but the mechanism of this proposed effect 
is still unclear. 
Interestingly, α-synuclein protein aggregation (the major component of LBs), has been shown to 
increase significantly with age in the SN, thereby facilitating the loss of dopaminergic neurons 
(Collier et al., 2011). Furthermore, accumulation of reactive oxygen species (ROS) is thought to be 
a common feature associated with the ageing brain, and is partially attributed to mitochondrial 
dysfunction due to decreased mitophagy (i.e. degradation of damaged/dysfunctional 
mitochondria) with ageing (Mammucari and Rizzuto, 2010; Green et al., 2011). 
1.2.1.2 Occupational toxin exposure 
Evidence in support of the environmental hypothesis, stems from the ground-breaking 
observations by Langston et al (1983) of a group of drug addicts in California who developed an 
acute parkinsonian syndrome which led to the identification of the neurotoxin, 1-methyl-4-phenyl-
1,2,3,6-tetra hydropyridine (MPTP). MPTP is a contaminant of a synthetic opiate that may cause 
parkinsonism through its toxic metabolite 1-methyl-4-phenylpyridinium (MPP+) (Langston et al., 
1983). Further investigation of this toxin later revealed that MPTP is metabolized to MPP+, which is 
subsequently transported by DA transporters into dopaminergic neurons where it ultimately inhibits 
mitochondrial function with long term exposure, and mimics the major clinical features of PD 
(Langston and Irwin, 1986). Apart from the young age of disease onset, and the associated 
pathology showing evidence of nigral cell loss without LB pathology, this form of parkinsonism was 
phenotypically similar to that described for sporadic PD cases, with good response to L-DOPA 
therapy (Langston and Irwin, 1986). The MPTP scenario was proof that long term exposure to an 
environmental agent with similar properties, or mechanisms as MPP+, may significantly alter 
dopaminergic neurotransmission in the SNpc, and could potentially result in movement 
abnormalities with strong resemblance to PD. Setting aside this earlier report of the few individuals 
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with MPTP-induced parkinsonism, MPTP is extremely rare in the environment, and is therefore 
regarded as a negligible cause of PD (McCormack et al., 2002). 
Selective occupations are considered to be strong risk factors for PD. In general, farmers and those 
with agricultural or rural occupations are thought to have a higher risk of developing PD, possibly 
due to long term exposure to selective pesticides, or other environmental factors (Greenamyre 
and Hastings, 2004; Hancock et al., 2008). Studies by Tanner and colleagues suggests a 3-fold 
increased risk of PD with long-term occupational exposure to paraquat and rotenone (Tanner et 
al., 2011). Paraquat is a widely used broad-spectrum herbicide, which is thought to have 
neurotoxic properties due to its structural similarity to the active metabolite of MPTP (i.e. MPP+) 
(Wesseling et al., 2001). Paraquat is also known to generate ROS by redox cycling; a mechanism 
which has been shown to induce dopaminergic damage in vivo (FisheIlett et al., 1974). 
Additionally, systemic injection of paraquat has been shown to elicit a dose-dependent decrease 
in voluntary movement, and DA cell count in the SNpc of mice models (Brooks et al., 1999; 
McCormack et al., 2002). 
Similar to paraquat, long-term exposure to rotenone is also thought to have an equally destructive 
effect on dopaminergic neurons as paraquat. Rotenone is a naturally occurring compound that 
is found in the roots and leaves of several plant species, and is extensively used as an insecticide 
(Cannon and Greenamyre, 2011). Rotenone has previously been shown to be a selective inhibitor 
of mitochondrial complex I, which is interestingly one of the mechanisms implicated in PD 
pathogenesis (Ravanel et al., 1984; Parker et al., 1989).  
Mining and welding are two other frequently discussed occupations, which generally involve long-
term exposure to high levels of various metals (e.g. zinc, copper, lead, and manganese). The 
impact of prolonged metal exposure is evident from in vivo brain imaging, which reveal a 
consistent increase in iron concentration in selective regions of the brain, where it is thought to 
contribute to process of neurodegeneration (Gerlach et al., 2006; Oakley et al., 2007). High levels 
of manganese (Mn) exposure has also been linked to striatal DA depletion, extrapyramidal 
dysfunction, and parkinsonism (Khalid et al., 2011). Additionally, Mn is thought to be a putative 
modulator of DA release, with a neurotoxic effect on mitochondrial function leading to the 
impairment of cellular energy metabolism (Schapira, 2007). 
How, and if environmental factors interact with genetic factors to trigger the onset of PD, remains 
unclear. Although numerous studies have reported a positive association between selective 
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pesticide exposure and PD, a positive association has not been consistently made for a single 
agent/toxin to date. The general conclusion is that outside of a few rare cases, it is highly unlikely 
that exposure to a single environmental agent on its own, may account for the significant number 
of sporadic PD cases 
1.2.1.3 Dose-dependent cigarette smoking, and coffee consumption 
Despite the numerous adverse health effects associated with cigarette smoking, a growing 
number of studies suggests a reduced risk of PD in long term smokers (Hernán et al., 2002; Demers 
et al., 2014). In a study by Quik et al. (2006), laboratory animals were treated with a compound 
known to destroy dopaminergic neurons of the SNpc, with half of these animals having received 
nicotine in their water supply. The researchers found that the levels of DA transmission were greater 
in the nicotine-treated animals than in the controls. Another study assessed the role of nicotine in 
transgenic rats with movement abnormalities similar to that observed in PD patients (Bordia et al., 
2010). Systemic dose-dependent nicotine injection was shown to significantly improve the 
voluntary movements in these rats, but the mechanisms underlying this association remain 
unclear. However, a number of theories have been proposed to explain the putative 
neuroprotective effect of smoking, the most likely of which involves the ability of nicotine to inhibit 
monoamine oxidase B (MAO-B), and stimulate acetylcholine receptors, which is thought to have 
a role in DA release (Fowler et al., 1996; Quik and Kulak, 2002). However, given that more than 
4000 components make up cigarettes, no single agent/substance can be conclusively isolated 
as the neuroprotective agent responsible for this effect (Demers et al., 2014). It should also be 
noted that the number of years spent smoking, rather than the number of cigarettes smoked per 
day, is associated with a reduced risk of PD (Kachergus et al., 2005). 
Similarly, a dosage-dependent reduced risk of PD has been suggested for coffee consumption 
(Hernán et al., 2002). Case-control studies have consistently reported this correlation in several 
follow-up studies (Paganini-Hill, 2001; Qi and Li, 2013). The proposed mechanism by which caffeine 
confers this effect has been demonstrated in numerous animal studies, in which dose-dependent 
caffeine injection was shown to mildly improve motor deficits in transgenic mice, possibly via the 
inhibition of the adenosine A2 receptor which is thought to moderately alleviate the severity of 
selective PD motor deficits (Morelli and Wardas, 2001; Xu et al., 2005). 
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Despite the increasing number of environmental factors that have been investigated for their 
potential role in PD, only a positive family history, advancing age, dose-dependent caffeine 
consumption, and long-term smoking have provided consistent results of a strong association with 
risk for PD. 
1.3 The genetic aetiology of PD 
Despite extensive progress over the last decade, the aetiology of PD remains poorly understood. 
Without a conclusive answer as to what causes the disease, it may prove difficult to uncover novel 
drug targets or develop more effective drug treatments for the disorder. Although the majority of 
reported PD case are of sporadic origin (~90%), the last decade has resulted in a growing body 
of literature in support of the genetic hypothesis for PD. It is mainly through the study of rare large 
families with clear Mendelian inheritance, that several causative genes have been identified, 
proving that the contribution of genetics to PD may be greater than previously thought. A 
summary of the most established genes is outlined in Table 1.1. 
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Table 1.1 List of genes directly implicated in familial PD [taken from (Trinh and Farrer, 2013)]. 
Gene Locus AAO (years)  Mutations identified Protein Protein Function 
Dominantly inherited genes associated with late-onset PD 
SNCA PARK1/4 30–80 A30P; E46K; A53T; gene 
duplications and triplications 
α-synuclein Plays a role in synaptic vesicle recycling and 
promotes exocytosis  
LRRK2 PARK8 32–79   7 point mutations leucine rich repeat kinase 2 Plays a role in chaperone-mediated autophagy, 
cellular and protein interactions and cell signalling 
VPS35 PARK17 40–68 Missense:  D620N vacuolar protein sorting 35 Mediates cargo recognition of early endosomes 
and membrane recruitment 
EIF4G1 PARK18 50-80  Missense: R1205H eukaryotic translation 
initiation factor 4 gamma 1 
mRNA translation processes 
Recessively inherited juvenile genes associated with early-onset PD 
parkin PARK2 12-58 Various point mutations; exonic 
rearrangements 
Parkin Ubiquitination and proteasomal function 
PINK1 PARK6 18-56 Various point mutations; rare, 
large deletions 
PTEN putative induced 
kinase 
involved in mitochondrial maintenance 
DJ – 1 PARK7 24–39 Point mutations; large deletions Oncogene DJ-1 involved in mitochondrial maintenance  and 
protection during oxidative stress   
ATP13A2 PARK9 10–33 Point mutations P5 subfamily of ATPase’s Plays  a role in lysosome-mediated autophagy 
AAO = Age at onset 
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1.3.1 Inheritance patterns 
1.3.1.1 Autosomal dominant PD 
Autosomal dominant (AD) disorders  generally present with a clinical and pathological phenotype 
similar to that observed in sporadic PD cases (Carr et al., 2003). Dominant inheritance is generally 
characterized by the presence of one mutation, on one allele (i.e. one gene copy inherited from 
either parents - heterozygous) is sufficient to cause disease. Additionally, at least one carrier of the 
disease-causing allele must be present in every successive generation, and the disease-causing 
allele must be transmitted to at least 50% of all the offspring of an affected parent (Klein and 
Schlossmacher, 2006). 
1.3.1.2 Autosomal recessive PD 
Autosomal recessive (AR) disorders are generally defined by the following: (1) two identical 
mutations [i.e. one on each allele, inherited from both parents, (homozygous)], or two different 
mutations [i.e. one on each allele, inherited from both parents, (compound-heterozygous)] are 
required to cause disease and (2); the presence of several affected members in one generation, 
with clinically asymptomatic parents and (3), the offspring of affected parents have a 25% risk of 
inheriting the disease-causing alleles. Lastly, patients with ARPD generally present with an earlier 
age of disease onset, and often demonstrate slower disease progression (Klein et al., 2007). It 
should be noted that heterozygous mutations may also result in disease. The most common 
pathogenic mechanism for heterozygous loss-of-function mutations is thought to be 
haploinsufficiency (i.e. wherein a single functional copy of a gene does not produce enough 
protein to bring about a wild-type condition) (Huang et al. 2010). Variable penetrance of 
heterozygous mutations is thought to be due to environmental factors, epigenetic effects, genetic 
modifiers or a combination of the three (Klein et al., 2007). 
An estimated 5–10% of individuals with PD are classified as familial patients because they have 
been shown to carry heritable, disease-associated mutations in a series of genes referred to as 
the PARK genes (Lesage and Brice, 2009). To date, eight PARK genes have been identified which 
encode: SNCA (α-synuclein - PARK1/4), LRRK2 (leucine-rich repeat kinase 2 - PARK8), VPS35 
(vacuolar protein sorting 35 - PARK17), and EIF4G1 (eukaryotic translation initiation factor 4-
gamma 1 - PARK18), all of which show a dominant inheritance pattern. The remaining four genes 
are associated with a recessive inheritance pattern and encode: parkin (PARK2), PINK1 (PTEN-
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Induced Kinase 1 - PARK6), oncogene DJ-1 (PARK7), and ATP13A2 (ATPase type 13A2 - PARK9) 
(Spatola and Wider, 2014). These genes will be discussed in more detail in the following sections. 
1.3.2  PD-causing genes 
1.3.2.1 SNCA / PARK1/4 
A key discovery in the elucidation of familial PD genes was the identification of an A53T mutation 
in SNCA, first identified in a large Italian pedigree with ADPD (Polymeropoulos et al., 1996). This was 
the first real evidence that a single gene mutation could cause PD, and this same mutation was 
subsequently identified in five unrelated Greek families (Golbe et al., 1996). Since then, four 
additional mutations, namely: A30P, E46K, H50Q, and G51D have been discovered (Krüger et al., 
1998; Zarranz et al., 2004; Appel-Cresswell et al., 2013; Lesage et al., 2013). Mutations in SNCA are 
extremely rare, with even fewer reports of gene duplications, or triplications in families with SNCA 
mutations (Singleton et al., 2003; Fuchs et al., 2007).  
Only the clinical phenotypes of the A30P, E46K, and A53T mutation have been extensively studied. 
A30P and E46K are associated with late disease onset (ranging from 54–76 years) with mild 
dementia and visual hallucinations, respectively (Kruger et al., 2001; Zarranz et al., 2004). Carriers 
of the A53T mutation have the earliest-disease onset (ranging from 36–58 years) leading to 
cognitive decline and dementia (Athanassiadou et al., 1999). The clinical phenotype associated 
with SNCA multiplications depends on dose: triplication carriers (4 copies) develop typical PD 
features with severe dementia, whereas duplication carriers (3 copies) may manifest a variety of 
Lewy body spectrum disorders (e.g. Dementia with Lewy bodies) (Ross et al., 2008). 
Alpha-synuclein (αSYN, SNCA protein) is unique in that it contains a highly hydrophobic central 
region containing a non-amyloid-β component, and has a tendency to self-aggregate and form 
protofibrils (Giasson et al., 2001). This tendency to self-aggregate is what makes αSYN important 
to PD pathology, as this protein is the main component of LBs (Kubo et al., 2005). Structurally, αSYN 
consists of three domains (Appendix A. Figure 1.5), and is highly expressed in the presynaptic nerve 
terminals, which may suggest a role in synaptic transmission (Kahle et al., 2000; Nuscher et al., 
2004). 
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1.3.2.2 LRRK2 / PARK8 
In 2004, two independent groups simultaneously reported the discovery of mutations in LRRK2 as 
the second causal link to ADPD (Paisán-Ruíz et al., 2004; Zimprich et al., 2004). Six mutations were 
originally found in numerous families worldwide, these include R1441C, R1441G, R1441H, Y1699C, 
N1437H, and the I2020T mutation (Funayama et al., 2002; Paisán-Ruíz et al., 2004; Zimprich et al., 
2004). With the exception of the R1441G mutation which was found in more than 8% of familial PD 
patients from the Basque population(González-Fernández et al., 2007), all the other mutations 
mentioned above are rare. By contrast, the LRRK2 G2019S mutation is the most common PD-
associated mutation (Di Fonzo et al., 2005), reported in at least three different founder populations 
(Klein and Lohmann-Hedrich, 2007). A founder population is generally established by a small 
number of people with limited genetic variation. As the population grows, any mutations 
harboured by this population become increasingly prevalent (Neuhausen, 2000). The G2019S 
mutation has been reported in approximately 41% of sporadic and 37% of familial PD patients 
from the North African Arab population, in 18.3% of Ashkenazi Jewish PD patients (and 1.3% of 
controls) (Lesage et al., 2006, Ozelius et al., 2006), and in 1-7% of familial PD populations of 
European descent (Zabetian et al., 2006). However, it should be noted that G2019S is relatively 
rare, or completely absent outside of the above mentioned founder populations (Guedes et al., 
2010). In addition, G2019S has been shown to have age dependent, incomplete penetrance as 
revealed by reports of a healthy 91 and 95 year old carrier of the mutation (Gaig et al., 2006; 
Carmine et al., 2006). 
A broad phenotypic spectrum has been reported per LRRK2 mutation, as the clinical phenotype 
can be more or less severe and the age at onset (AAO) may vary depending on the mutation, 
albeit with a large overlap (Haugarvoll et al., 2008). Generally, patients present with late disease 
onset, show good response to L-DOPA therapy, with additional features including amyotrophy 
and severe dystonia (Hasegawa and Kowa, 1997). Similarly, the neuropathology of patients with 
LRRK2 mutations is highly variable. For example, neuropathological findings from 49 patients 
revealed α-synuclein positive pathology, tau pathology, and the more common LB pathology 
(Wider et al., 2010). 
LRRK2 consists of seven functional domains (Appendix A. Figure 1.6), and is thought to play a role 
in the regulation of signal transduction cascades through its dual enzymatic activities (i.e. GTPase 
and Kinase activity) (Cardona et al., 2014). 
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1.3.2.3 VPS35 / PARK17 
The D620N mutation in VPS35 is a more recently identified cause of PD. This mutation was 
concurrently described in a Swedish PD family by Vilariño-Güell et al. (2011), and in three Austrian 
families by Zimprich et al. (2011). In addition, D620N has also been shown to be the cause of late-
onset ADPD in at least 13 unrelated families of largely Caucasian, or Japanese descent (Ando et 
al., 2012; Lesage et al., 2012). 
The phenotype of these families was similar to that observed in sporadic PD cases, with learning 
disabilities, dementia and psychosis being described as part of the clinical profile of the original 
Swiss family (Vilariño-Güell et al., 2011; Zimprich et al., 2011). The average AAO for carriers of the 
VPS35 D620N mutation is 52 years (ranging from 37–72 years), with age dependent incomplete 
penetrance (Zimprich et al., 2011).  
VPS35 is part of the retromer complex that is involved in the transport of endosomes back to the 
trans-Golgi, and in the sorting of receptors for hydrolases, thus affecting vacuole/lysosomal 
function and biogenesis (Derivery et al., 2009; Harbour et al., 2010).  
1.3.2.4  EIF4G1 / PARK18 
In 2011, Chartier-Harlin and colleagues reported five sequence variants with a possible role PD in 
EIF4G1 using genome-wide linkage analysis. However, of these sequence variants, namely: A502V, 
G686C, S1164R, R1197W and R1205H, only the latter has been shown to be pathogenic (Chartier-
Harlin et al., 2011). The co-segregation of the R1205H mutation was first described in a French 
family with late disease onset, and LB pathology. However, several unaffected carriers of this 
mutation have recently been described, possibly due to incomplete penetrance (Schulte et al., 
2012; Nuytemans et al., 2013). 
Functionally, EIF4G1 has been implicated in mRNA translation processes (the final step in protein 
translation) (Chartier-Harlin et al., 2011; Schulte et al., 2012). Based on the small  number of patients 
described so far, the clinical phenotype of R1205H carriers has been described as mild PD with 
disease onset ranging from 50 to 80 years of age, with diffuse LB pathology (Chartier-Harlin et al., 
2011). Similar to the D620N mutation in VPS35, the frequency of the R1205H mutation is extremely 
low, with estimates of 0.02–0.2% of the PD population (Tucci et al., 2012). Further studies are 
therefore warranted to ascertain the true contribution of this mutation to PD pathogenesis. 
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1.3.2.5  Parkin / PARK2 
The most frequently encountered form of ARPD is associated with mutations in parkin, encoding 
an E3 ubiquitin ligase protein. The identification of parkin was facilitated by the discovery of a 
microdeletion in a family with AR juvenile-onset (≤20 years of age) PD (Matsumine et al., 1997). 
Since the initial discovery, many research groups have identified more than 150 different 
mutations throughout the genomic region of parkin, and these include exonic deletions, insertions, 
and missense mutations. 
Parkin-linked ARPD is characterized by an early AAO (≤50 years), good response to L-DOPA 
treatment, and L-DOPA-induced dyskinesia with disease progression (Lücking et al., 2000). While 
carriers of parkin mutations present with typical PD features, the presence of LBs has only been 
reported in a few cases to date (Farrer et al., 2001; Khan et al., 2003). However, there have been 
reports of LB or tau pathology in carriers of compound-heterozygote mutations (van de 
Warrenburg et al., 2001; Pramstaller et al., 2005).  
Parkin consists of five functional domains (Appendix A. Figure 1.7), and is prominently expressed in 
both neuronal and glial cells (Shimura et al., 2000). In addition, parkin acts as a substrate-
recognition molecule during ubiquitination in the ubiquitin proteasomal system due to its function 
as an E3 ubiquitin-ligase (Moore, 2006). Loss-of-function mutations in parkin, are therefore thought 
to reduce or abolish ligase activity, and may also facilitate the neurotoxic accumulation of 
misfolded proteins (Shimura et al., 2000). 
1.3.2.6  PINK1 / PARK6 
Mutations in PTEN induced kinase 1 (PINK1), were first identified in a large consanguineous family 
from Sicily (Valente et al., 2001), and subsequently in several European families (Valente et al., 
2002). Mutations in PINK1 have been identified in numerous families worldwide, including a variety 
of missense and nonsense splice mutations (Valente et al., 2001. Estimates of prevalence from 
European and Asian populations, suggest that PINK1 mutations are the second most frequent 
cause of ARPD, with over 40 point mutations and rare instances of large deletions identified to 
date (Lesage and Brice, 2009). 
The clinical phenotype associated with PINK1 mutations is similar to that observed in patients with 
parkin-related PD. This includes slow disease progression, good response to L-DOPA, and frequent 
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L-DOPA-induced dyskinesia (Hatano et al., 2004). Additional features may also include sleep 
benefit, rest dystonia, and psychiatric problems (Hatano et al., 2004; Ibáñez et al., 2006). The first 
post-mortem report of a PD patient harbouring a PINK1compound-heterozygous mutation 
presented with neuronal loss in the SNpc, LBs formation and aberrant neurites in the reticular nuclei 
of the brainstem (Samaranch et al., 2010).  
PINK1 consists of three domains (one of which is putative) (Appendix A. Figure 1.8), and acts as a 
serine/threonine kinase which belongs to the Ca2+/calmodulin family (Valente et al., 2001). PINK1 
is ubiquitously expressed in the human brain, with prominent localisation in the inner mitochondrial 
membrane, and is thought to regulate mitochondrial morphology (Silvestri et al., 2005; Rothfuss et 
al., 2009). Moreover, PINK1 acts upstream of parkin in a common pathway which is thought to 
maintain mitochondrial function (Kawajiri et al., 2011). 
1.3.2.7  DJ-1 / PARK7 
Using an RT-PCR strategy, Bonifati and colleagues identified a deletion in exons 1 to 5 of DJ-1 that 
showed complete cosegregation with the disease allele in a large consanguineous Dutch family 
with ARPD (Bonifati et al., 2002). The linkage of the PARK7 locus to chromosome 1p36 was 
subsequently confirmed in another consanguineous family of Italian descent (Bonifati et al., 2003). 
The DJ-1 protein was absent in the Dutch family, while the protein appeared to be inactive in the 
Italian family, thus suggesting that mutations in DJ-1 may cause PD through a loss of function 
mechanism. Since the initial discovery, DJ-1 missense, truncating, splice site mutations, and several 
deletions have been described in different populations worldwide (Abou-Sleiman et al., 2003).  
Similar to parkin and PINK1-related PD, the clinical phenotype associated with mutations in DJ-1 
includes an early AAO, slow disease progression, and good L-DOPA response (Dekker et al., 2003). 
However, the frequency of DJ-1 mutations is significantly lower than that described for parkin or 
PINK1 mutations (Kumazawa et al., 2008). 
DJ-1 consists of a single functional domain (Appendix A. Figure 1.9), consisting of seven exons. DJ-
1 is largely cytoplasmic with prominent localization in the mitochondria, and is thought to play a 
role in protection of dopaminergic neurons in the presence of oxidative stress (Canet-Avilés et al., 
2004; Chen et al., 2005). 
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1.3.2.8 ATP13A2 / PARK9 
Mutations in ATP13A2 were first described in a single consanguineous family of Chilean descent, 
and are associated with a clinical syndrome called Kufor-Rakeb Syndrome (KRS) (Ramirez et al., 
2006). A number of pathogenic mutations have been described in both the homozygous and 
compound-heterozygous state, resulting in truncated forms of the wild-type protein (Ramirez et 
al., 2006; Ugolino et al., 2011). Mutant ATP13A2 is thought to result in the impairment of 
proteasomal pathways, and the premature degradation of the mutant ATP13A2 mRNA may also 
contribute to the variable aetiology of KRS (Park et al., 2011; Dehay et al., 2012).  
KRS has a broad spectrum of clinical features including widespread neurodegeneration, 
dementia, dystonia, with early-onset, L-DOPA-responsive parkinsonism (Ramirez et al., 2006). 
Additional features of pyramidal degeneration include cognitive dysfunction, and generalized 
brain atrophy (Behrens et al., 2010). There is considerable phenotypic variability even amongst 
family members, with rare cases of ataxia (Eiberg et al., 2012).  
ATP13A2 consists of 10 transmembrane domains (Appendix A. Figure 1.10), is located in lysosomal 
membranes and highly expressed in the mammalian brain (Ramirez et al., 2006). ATP13A2 is 
thought to be responsible for cation transport and the regulation of Mn levels, accumulation of 
which has previously been shown to be a strong risk factor for neurodegeneration (Schultheis et 
al., 2004). 
1.3.3  Genetic susceptibility alleles 
Apart from the above discussed PD-causing genes, candidate gene association studies have also 
implicated a number of other genes thought to confer an increased risk for PD (UK Parkinson’s 
Disease Consortium et al., 2011). Traditional association studies have explored disease risk 
associated with allelic variants in SNCA and LRRK2. The SNCA promoter region REP-1 polymorphism 
is associated with a 1.4-fold increased risk of familial PD (Mueller et al., 2005), while two common 
variants in LRRK2 (G2385R and R1628P) appear to increase the risk of both sporadic and familial 
PD by nearly two-fold, particularly in Asian populations (Bonifati, 2007).  
One of the more notable PD risk factors, are dominant mutations in MAPT (encoding the 
microtubule-associated protein tau) (Halliday et al., 2011). Meta-analyses studies have shown that 
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the H1 haplotype at the MAPT locus on chromosome 17q21.31, confers a 1.57-fold increased risk 
of PD (Wider et al., 2010).  
Given the presence of parkinsonism and LB pathology in patients with the AR lysosomal storage 
disorder Gaucher’s disease (GD), PD patients are routinely screened for mutations in 
glucocerebrosidase (GBA). GBA is a lysosomal enzyme that hydrolyses glucocerebroside, thereby 
releasing ceramide which acts as a second messenger during signal transduction (Tayebi et al., 
2003). Homozygous or compound heterozygous mutations in GBA cause GD, while heterozygous 
mutations have been found to increase the risk of PD (Sidransky et al., 2009). The largest 
sequencing study of GBA in a French population by Lesage et al. (2011) definitely confirms that 
heterozygous GBA mutations may increase risk of PD by more than 5-fold, thus making GBA one 
of the strongest risk factors for the disorder. 
The list of genetic risk factors identified to date is continuously increasing and currently includes 
over 20 independent loci. Interestingly, some studies suggest that the risk for PD increases with the 
number of risk alleles carried by a single individual, which could be indicative of an additive effect 
(Hill-Burns et al., 2011). 
1.3.4  PD and Spinocerebellar ataxias 
Among the list of Mendelian mutations that have been causally related to PD, spinocerebellar 
ataxias (SCAs) are one of the most interesting group of polyglutamine disorders caused by a CAG 
repeat expansion which codes for an elongated polyglutamine tract within the respective SCA 
proteins. SCAs are a heterogeneous group of autosomal dominantly inherited ataxia (i.e. lack of 
movement) disorder which belong to a larger group of polyglutamine disorders including 
Huntington’s disease, and Spinobulbar muscular atrophy (Rüb et al., 2013). SCAs are 
characterized by an earlier AAO, and increasing severity of clinical phenotypes in subsequent 
generations (a phenomenon known as anticipation) that correlates with larger repeat lengths 
(Schöls et al., 2004). Some of the more prominent features of SCA disorders include: muscle 
weakness, loss of tendon reflexes, slurring of speech, involuntary eye movements with associated 
symptoms of cardiomyopathy, scoliosis, diabetes mellitus, and cerebellar ataxia (Zoghbi, 1996). 
SCA consists of thirty-two different gene loci (SCA1 to SCA32), with the most common of which 
being SCA1, 2, 3, and 7 (Schöls et al., 2004). The general pathological hallmark of SCAs is 
characterized by progressive neuronal loss and gliosis which primarily affects the cerebellum and 
related structures in the CNS (Schöls et al., 2004; Klockgether, 2011). 
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For the purposes of the present study, particular emphasis was placed on the study of CAG repeat 
expansions at the SCA2 and SCA7 loci.  
The SCA2 locus, first described by Gispert et al. (1993) in a Cuban population, is the most frequent 
SCA subtype in various populations worldwide (Cancel et al. 1997). The genetic basis for the 
disease is a CAG repeat expansion above a certain threshold in exon 1 of SCA2 (Pulst et al., 1996). 
In normal individuals the CAG repeat is polymorphic in length, ranging from 14 to 30 repeats; 
repeats ranging between 30 and 34 are considered to be ‘intermediate’ (i.e. do not cause the 
disease phenotype), while the pathogenic SCA2 repeats consists of a pure, continuous stretch of 
34 to 59 CAGs (Giunti et al., 1998). Interestingly, SCA2 patients have been known to present with 
a clinical phenotype suggestive of pure parkinsonian without other neurological signs (Gwinn-
Hardy et al., 2000; Ragothaman et al., 2004). It therefore remains a challenge to correctly 
diagnosis SCA2 patients as the disease has wide phenotypic overlap with various disorders, 
including PD (Furtado et al., 2004; Wilkins et al., 2004). 
The expression of ataxin-2, the SCA2 protein product, has been previously described in the 
dopaminergic neurons of the SNpc (Huynh et al., 2007). Additionally, parkin, the most common 
cause of ARPD, has been shown to interact with ataxin-2. This interaction has been previously 
described in SCA2 siblings who were shown to exhibit neuronal loss in the SN, with prominent 
evidence of intranuclear ubiquitin and ataxin-2 associated inclusions (Armstrong et al., 2005; 
Huynh et al., 2007). Furthermore, parkin knockout mice studies by Huynh et al. (2007) have 
demonstrated that variation in endogenous parkin levels alters the steady-state levels of 
endogenous ataxin-2, and decreases ataxin-2 induced cytotoxicity in HEK293 cells (Huynh et al., 
2007). 
Spinocerebellar ataxia type 7 (SCA7) is characterized by prominent language impairment, and 
progressive loss of vision (Rüb et al., 2013). The underlying genetic cause is an expanded CAG 
repeat at the 5´ end of SCA7, which has been shown to co-segregate with the disease in several 
families (Stevanin et al., 2000). SCA7 CAG repeat alleles can be divided into the following 
categories: normal (<19 repeats), intermediate (28 to 33 repeats), reduced penetrance (34 to 35 
repeats), and pathogenic expansion (>36 repeats) (Sequeiros et al., 2010).  
Bryer and colleagues first described SCA7 as the second most prevalent SCA subtype, preceded 
only by SCA1, in the South African (SA) population (Bryer et al., 2003). Unlike the SCA1, which is the 
most frequent type of SCA in the SA Coloured, White and Indian populations, SCA7 occurs 
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exclusively in individuals of Black African ancestry, due to a common founder haplotype in this 
population group (Smith et al., 2012). Studies do indeed suggest that Black SA SCA7 positive 
patients are descended from a common ancestor. This is based on the observation that more 
than 50% of these patients are heterozygous for a common single nucleotide polymorphisms (SNP) 
(rs3774729) in the 3’ region of SCA7 (Greenberg et al., 2006; Scholefield et al., 2009). SNP’s are 
single-nucleotide substitutions of one base for another that occur in more than one percent of the 
general population, and serve as the most common type of genetic variation among people (Wu 
and Jiang, 2013). 
A recent report by Alves and colleague suggest that the autophagy lysosome pathway (ALP) 
may be impaired by the selective accumulation of mutant ataxin-7 in the cerebellum and 
cerebral cortex of SCA7 patients (Alves et al., 2014). Apart from the ubiquitin-proteasome system 
(UPS) which is mainly involved in the breakdown of short-lived proteins, the ALP represents the 
major mechanism by which intracellular long-lived proteins, and cytoplasmic organelles can be 
degraded (Rubinsztein, 2006). Formation of mutant ataxin-7 aggregates is thought to lead to the 
production of toxic protein fragments, and impairment of the ALP due to excess protein 
aggregation (Alves et al., 2014). The removal of ataxin-7 protein aggregates, through the 
activation of the autophagy pathway has been shown to interfere with the potential toxicity of 
these aggregates, and thereby alleviate disease progression in mouse models of the disease 
(Ravikumar et al., 2004; Tanaka et al., 2004). 
1.4  Potential mechanisms involved in PD pathogenesis 
The study of rare, inherited genes underlying familial forms of PD has provided insight into the 
molecular mechanisms of disease pathogenesis. Mutations in these genes have been functionally 
linked to several molecular pathways implicated in neuronal apoptosis in several 
neurodegenerative disorders, including PD (Figure 1.11). However, only two clearly defined 
disease mechanisms, namely: mitochondrial dysfunction and impairment of the protein 
degradation pathways (consisting of the UPS, and the ALP) will be discussed in the following 
sections, with an emphasis on their normal function, and how their dysfunction/impairment may 
contribute to disease pathogenesis.
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1.4.1 Mitochondrial dysfunction and oxidative stress 
A number of proteins associated with familial PD have an important role in maintaining 
mitochondrial function, In particular, the mitochondrial kinase PINK1, and the cytosolic E3 ubiquitin 
ligase parkin are thought to act in a common pathway to regulate mitochondrial function (Gegg 
et al., 2010). Several lines of evidence suggest that mitochondrial dysfunction may be attributed 
to reduced complex I activity in PD patients, and reduced mitochondrial membrane potential 
accompanied by increased ROS production in PD cell models (Gegg et al., 2010; Thomas et al., 
2011). Mutations in parkin and PINK1 are the most common cause of ARPD, with both proteins 
being highlighted as key role players in the clearance of damaged mitochondria via 
autophagy—a process known as mitophagy (Matsuda et al., 2010). A number of studies have 
provided clues as to how PINK1 may regulate parkin-mediated mitophagy, and how PD-
associated PINK1 and parkin mutations result in defective mitophagy. One such study showed 
that PINK1 knockdown in SH-SY5Y cells induces mitophagy through effects on oxidative stress and 
mitochondrial fission, whereas overexpression of PINK1 stabilised mitochondrial networks (Dagda 
and Chu, 2009). This observation is interesting because defects in autophagy/mitophagy have 
been shown to mimic a series of reported PD features such as impaired motor coordination, and 
the accumulation of protein aggregates in residual neurons (Narendra et al., 2012). Mitochondrial 
protection in the presence of excess oxidative stress is mediated by the kinase activity of 
PINK1(Matsuda et al., 2010). PINK1 mutations are therefore thought to result in increased ROS, 
which is known to induce neuronal apoptosis (Gandhi et al., 2009). Notably, strong evidence 
suggests that another AR cause of PD, namely DJ-1, may maintain mitochondrial function in the 
presence of excess oxidative stress, due to its interaction with mitochondrial protein mortalin, 
which maintains mitochondrial homeostasis and antagonizes ROS (Burbulla et al., 2010; Thomas et 
al., 2011).
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Figure 1.11 Putative mechanisms underlying the pathogenesis of PD. An axon of a presynaptic neuron (blue), a dopaminergic neuron of the SNpc (green), 
and a dendritic spine of a medium spiny neuron (orange) are illustrated. Under normal cellular conditions, SNCA (1) promotes exocytosis in presynaptic 
terminals; LRRK2 (2) facilitates the postsynaptic phosphorylation of endophilin A, and the release of clathrin-coated endocytic vesicles. VPS35 (3) mediates 
receptor recycling via cargo recognition of early endosomes, which is also required for the normal functioning of lysosomal acid hydrolase GBA (4). Parkin (5) 
is involved in proteasomal function and mitochondrial maintenance together with PINK1 (6), while DJ-1 (7) maintains mitochondrial function in the presence of 
oxidative stress. ATP13A2 (8) has a role in lysosome-mediated autophagy, and MAPT (Microtubule-associated protein tau) (9) has a role in the regulation of 
cargo trafficking and delivery [taken from (Trinh and Farrer, 2013)].
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1.4.2 Failure of protein degradation systems 
Protein degradation systems are primarily involved in the clearance of misfolded proteins, and 
dysfunctional organelles such as defective mitochondria (Korolchuk et al., 2010). The two major 
degradation systems are the UPS, and ALS, however, only the UPS will be discussed in this section 
as it is the principal mechanism through which proteins are degraded in the mammalian cytosol 
and nucleus (Glickman and Ciechanover, 2002). The UPS consists of proteases located in 
specialised protein complexes, and proteasomes which form the main machinery for protein 
degradation. The main function of the proteasomes is to target cytosolic proteins for regulated 
degradation in a sequential series of reactions catalysed by ubiquitin activating enzymes (E1), 
ubiquitin conjugating enzymes (E2), and ubiquitin ligases (E3) which transfer the ubiquitin 
polypeptide to target proteins as part of the UPS (Figure 1.12). Once a chain of several ubiquitin 
molecules has been formed, this is then added to the target protein (a process referred to as 
polyubiquitination), which is recognized by a series of proteases (i.e. the 26S proteasome) and 
degraded through proteolysis (McNaught et al., 2004). Given the presence of ubiquitinated 
proteins in LBs, it has been proposed that abnormal protein accumulation, resulting from the 
impairment of the UPS, may be a key feature of PD pathogenesis. Proteasome inhibitors have 
been shown to induce selective degeneration of cultured dopamine neurons with the formation 
of LB-like inclusions in model systems (Zeng et al., 2006). Systemic administration of proteasome 
inhibitors has also been shown to induce parkinsonism in experimental animals, and elicit selective 
degeneration of dopaminergic neurons, in which inclusion bodies that stain positively for both 
αSYN  and ubiquitin are formed (McNaught et al., 2004). Loss-of-function mutations in parkin are 
thought to inhibit, or significantly impair the process of ubiquitination, because of its role as an E3 
ubiquitin ligase (Shimura et al., 1999).
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Figure 1.12 The ubiquitin-proteasome system (UPS). The steps by which the UPS clears unwanted proteins: ATP-dependent activation of ubiquitin monomers; 
labelling of unwanted/damaged proteins with chains of activated ubiquitin molecules by CHIP; transport of ubiquitinated proteins to the proteasome by chaperone 
molecules such as heat shock proteins (HSPs); recognition and unfolding of ubiquitinated proteins by proteasome regulators; and ATP-dependent degradation 
of unwanted proteins by the proteasome. The red circles represent ubiquitin [taken from (Goldberg 2003)]. 
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1.5  PD research in sub-Saharan Africa 
The genetic aetiology of PD in Black patients from Sub-Saharan Africa (SSA) is poorly 
characterized, as the disorder is generally perceived to have lower prevalence and incidence 
because of the relative youthfulness of the SSA population (<5% are over the age of 65), scarcity 
of published reports, socioeconomic issues and cultural misconceptions which generally view 
neurologic disorders as being part of normal ageing (Dotchin et al., 2012). To the best of our 
knowledge, only nine studies have investigated the underlying genetic aetiology of PD in SSA 
populations (Table 1.2), while no incidence studies have been published to date (Dotchin et al., 
2008; Lekoubou et al., 2014). The increasing knowledge gap of PD in SSA populations is further 
hampered by many challenges. These include the exorbitant cost of medication, the scarcity of 
movement disorders specialists, a general lack of public awareness of PD, and the negative 
stigmatization associated with affected individuals, partly due to negative cultural perceptions 
associated with neurological diseases in general (Dotchin et al., 2007; Mshana et al., 2011). The 
need for comprehensive research of PD in SSA will become considerably more important given 
the current demographic transition. A greater proportion of aging populations worldwide, are 
projected to survive to an older age by 2050, thereby facilitating the increased prevalence of 
age-related diseases such as PD (Bach et al., 2011; Dotchin et al., 2012). This demographic 
transition is evident from population estimates which show that in 2005, there was approximately 
34 million people aged 60 years and over in SSA. This number is now projected to increase to over 
67 million by 2030 (Dotchin et al., 2012). Interestingly, the number of aging populations in SSA is 
growing more rapidly than that of the developed countries. For example, the prevalence of PD is 
projected to increase by nearly 200% in Tanzania alone (Dotchin et al., 2012). This figure is 
significantly greater than the estimated 92% projected increase in the number of people over the 
age of 60 years in countries such as Europe, the United States and Canada over the same time 
period (Bach et al., 2011).  
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Table 1.2 Summary of genetic studies performed on Black PD patients from SSA [(taken from (Blanckenberg et al., 2013)]. 
Gene Country No. of 
patients 
Screened/Methods Results Reference 
LRRK2 Black Africans 
(country not 
specified) 
4 Exon 41 (sequencing) No mutations found (Lesage et al., 2006) 
South Africa 12 Exons 1, 2, 10, 15, 27, 41 and 49 + 
G2019S (exon dosage-MLPA) 
No mutations found (Keyser et al., 2010) 
South Africa 16 G2019S (HRM) No mutations found (Bardien et al., 2010) 
Ghana 54 Exons 31 and 41 (sequencing) No mutations found (Cilia et al., 2012) 
Nigeria 57 Exons 31 and 41 (sequencing) No mutations found (Okubadejo et al., 2008)] 
Zambia 17 Exons 29 to 48 (sequencing) No mutations found (Yonova-Doing et al., 2012) 
Zambia 22 All 51 exons (sequencing) No mutations found (Yonova-Doing et al., 2012) 
Zambia 29 Exons 1, 2, 10, 15, 27, 41 and 49 + 
G2019S 
No mutations found (Yonova-Doing et al., 2012) 
SNCA South Africa 12 All 6 exons + A30P (exon dosage-
MLPA) 
No mutations found Keyser et al., 2010) 
Zambia 29 All 6 exons + A30P (exon dosage-
MLPA) 
No mutations found (Yonova-Doing et al., 2012) 
Zambia 39 All 6 exons (sequencing) No mutations found (Yonova-Doing et al., 2012) 
VPS35 and 
EIF4G1 
South Africa 18 D620N mutation (KASP assay), 
R1205H mutation (KASP assay) 
No mutations found (Blanckenberg et al., 2014) 
Parkin South Africa 17 All 12 exons (SSCP and HRM) No mutations found (Bardien et al., 2009; Haylett et 
al., 2012) 
17 All 12 exons 
(exon dosage-MLPA) 
Duplication of exon 2 & deletion of exon 9 
in one proband and an affected sibling. 
Heterozygous G430D mutation and 
deletion of exon 4 in another proband 
(Haylett et al., 2012; Keyser et al., 
2010) 
Zambia 12 All 12 exons (sequencing) No mutations found (Yonova-Doing et al., 2012) 
Zambia 29 All 12 exons (exon dosage-MLPA) Heterozygous deletions of exon 2 and 
exon 4 in one proband 
(Yonova-Doing et al., 2012) 
Nigeria 57 All 12 exons (sequencing) No mutations found (Okubadejo et al., 2008) 
PINK1 South Africa 12 All 8 exons (exon dosage-MLPA) No mutations found Keyser et al., 2010) 
South Africa 18 All 8 exons (HRM) No mutations found Keyser et al., 2010) 
Zambia 12 All 8 exons (sequencing) No mutations found (Yonova-Doing et al., 2012) 
Zambia 29 All 8 exons (exon dosage-MLPA) No mutations found (Yonova-Doing et al., 2012) 
DJ-1 South Africa 12 Exons 1, 3, 5 and 7 (exon dosage-
MLPA) 
No mutations found Keyser et al., 2010) 
Zambia 12 All 7 exons (sequencing) No mutations found (Yonova-Doing et al., 2012) 
Zambia 29 Exons 1, 3, 5 and 7 (exon dosage-
MLPA) 
No mutations found (Yonova-Doing et al., 2012) 
HRM, high-resolution melt; MLPA, multiplex ligation-dependent probe amplification. SSCP, single-strand conformation polymorphism. 
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1.6 PD research in South Africa 
Cosnett and Bill (1988) performed one of the earliest studies on PD, which investigated the 
prevalence of the disorder in over 2000 inpatient neurological consultations in three Durban based 
hospitals. They found the prevalence of PD to be uncommon in the Black population groups, 
relative to White and Indian patients from the same population, and of the same age bracket 
(between 60 and 80 years) (Cosnett and Bill, 1988). Despite research efforts, very little is still known 
of the molecular aetiology of PD in the unique Black SA population, which may be partly 
attributed to ascertainment bias. In the context of this population, the term ‘Black population’ 
refers to a group of individuals whose ancestry can be directly traced to the African continent. 
Moreover, this ethnic group is comprised of individuals who speak indigenous African languages 
including: IsiZulu, Northern and Southern Sesotho, IsiXhosa, IsiNdebele, Sepedi, Tsonga, Tshivenda, 
and Setswana. To date only six published studies have investigated the underlying genetic factors 
which may account for PD in selected ethnic groups from the SA population. Based on these 
studies, mutations in the known PD-causing genes have been found to be a minor cause of the 
disorder, therefore suggesting that a novel gene may account for the disease onset in the majority 
of SA Black patients screened thus far (Bardien et al., 2009; Keyser et al., 2010; Haylett et al., 2012; 
Blanckenberg et al., 2014). This is a highly plausible hypothesis, given that the Black ethnic 
population harbours one of the oldest, most unique genetic ancestries, with the greatest level of 
diversity worldwide (Ramsay et al., 2011). Yet, no molecular genetic studies of PD have exclusively 
focused on the Black SA population group to date. A comprehensive genetic study, primarily of 
this group, could prove invaluable in the elucidation of novel, yet unexplored disease-causing 
pathways for PD. This is the focus of the present study. 
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1.7 Mutation detection techniques 
A number of different mutation screening techniques were used in the present study, and the 
underlying principle of each technique will be discussed in the next section. These include the use 
of Sanger sequencing and high-resolution melt (HRM) for the detection of single base pair 
changes and small insertions and deletions, and multiplex-ligation dependent probe amplification 
assay (MLPA) for identification of exonic rearrangements. In addition, a next generation 
sequencing approach (NGS) was used for comprehensive and systematic screening of all known 
involved in neurodegenerative disorders. 
1.7.1 Sanger sequencing 
Sanger sequencing is a first generation sequencing technology which uses dideoxy nucleotide 
triphosphates (ddNTPs) as DNA chain terminators so that the labelled fragments can be separated 
according to size using electrophoresis. This sequencing approach allows for elucidation of DNA 
sequence reads and the detection of point or frameshift mutations using the ABI sequencing 
machine (e.g. ABI 3130XL Genetic Analyzer), which uses differently coloured fluorescent dyes to 
label each of the four ddNTPs (A,T,C,G). Amplified single stranded target DNA is used as a 
template and extended by a DNA polymerase, separated by capillary electrophoresis and is 
detected by laser excitation as the dye-labelled fragments migrate through a transparent window 
of the capillary array to yield a sequencing result (Dianzani et al., 1993). 
1.7.2 High-resolution melt 
HRM is a rapid approach for SNP genotyping, and cheaper alternative to Sanger sequencing with 
regards to mutation screening. The HRM technique is based on a melting (dissociation) curve 
analysis, and can be considered to be a next-generation application of amplicon melting analysis 
(Vossen et al., 2009). HRM allows for the simple characterization of DNA samples based on their 
disassociation/melt profile behaviour, used to detect single base pair differences between 
samples. DNA sequences are discriminated according to their GC content, strand 
complementarity and sequence length. HRM is essentially a post PCR technique performed on 
high-throughput instrumentation, and dedicated analysis software, which facilitate the detection 
of small changes in sequence variation using specialized double-stranded DNA (dsDNA) 
intercalating dyes (e.g. SYBR® Green I, or EvaGreen®) (Li et al. 2012). These dyes are highly 
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fluorescent when bound to dsDNA, and become gradually less fluorescent when bound to single 
stranded DNA (i.e. ssDNA). As the strands separate, the dye is released, causing a decrease in 
fluorescence with the increasing temperature. HRM instrumentation collects and analyses 
fluorescent signals in real time, thereby characterizing the different DNA fragments, such that the 
fluorescence (y-axis) is plotted against temperature (x-axis) (Figure 1.13). Since different DNA 
sequences melt at slightly different rates, they can be analysed and compared to a wild-type 
sample using the respective melt curves. Any PCR products which exhibit an altered melt profile, 
distinct to that of the wild-type control sample, must be confirmed using Sanger sequencing to 
identify and confirm the sequence variation.  
Figure 1.13 Illustration of high-resolution melt curve analysis. The green and red boxes indicate the pre- and post-
melt regions, used for data normalization. RFU denotes relative fluorescence units (taken from http://www.bio-
rad.com/en-za/applications-technologies/high-resolution-melting). 
1.7.3 Multiplex ligation-dependent probe amplification assay 
MLPA is the most widely used approach for the detection of exonic rearrangements [i.e. copy 
number variation (CNV)]. MLPA can be divided into five steps as illustrated in Figure 1.14: (1) DNA 
denaturation and hybridization of probes, (2) ligation reaction, (3) PCR amplification, and (4) 
separation of PCR products using capillary electrophoresis. Once the PCR products have been 
separated, the peak patterns are than compared to reference samples. A normal sample has a 
peak ratio of 1 (range of 0.7-1.3), a heterozygous deletion has a peak ratio of 0.5 (range 0.3 
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– 0.7), while a homozygous deletion has a peak ratio of zero. Heterozygous duplications have a
peak ratio of 1.5 (range 1.3 – 1.7), and homozygous duplications have peak ratio of 2 (range 1.7 
– 2.3) (Schouten et al. 2002). Possible CNVs must be validated by Sanger sequencing and
quantitative-PCR (qPCR). 
Figure 1.14 Outline of the Multiplex ligation-dependent probe amplification reaction. Each amplicon generates a 
unique fluorescent peak and each peak represents a specific exon. Peak height differences reflect CNV detected 
by the MLPA probes [taken from (Schouten et al. 2002)]. 
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1.7.3.1 Data interpretation and presentation of results using qPCR 
Possible CNVs detected using MLPA can be graphically represented as follows: after the 30th 
cycle of the DNA melting process using the LightCycler® 96 Real-time PCR system, the wild type 
samples has a characteristic peak height and pattern corresponding to both the reference 
amplicon and the analysed amplicon (Figure 1.15 a, green curve). In the case of samples with 
CNVs, the peak pattern is distorted. When one of the exons of the analysed gene undergoes a 
deletion, its peak decreases and, at the same time, the peak of the reference amplicon increases 
(Figure 1.15 a, red curve). The situation is reversed in the case of exon amplification, with the peak 
of the reference amplicon decreasing and the peak of the analysed amplicon increasing (Figure 
1.15 a, blue curve). In order to observe these differences, the results are compared with DNA 
samples with an unchanged copy number of templates for each of the amplified fragments. 
These results are subsequently represented in a bar graph format (Figure 1.15 b), such that the 
highest peak values are determined, and the ratio thereof is then compared to that of the 
reference peak. The peak height ratio should be 0.5X for samples with a deletion (n copies) and 
1.5X for samples with a duplication (3n copies), whereas the peak height ratio for a wild type 
sample should be 1X (2n copies) (Borun et al., 2014).  
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Figure 1.15 Conceptual qPCR graph presenting an outline of the method. (a) Melting profile containing examples 
of possible genotypes. Green curve represents wild type sample, blue curve represents sample with possible exonic 
amplification of the target amplicon, red curve represents a sample with possible deletion of the target amplicon, 
and the purple curve represents a sample with point mutation in the target amplicon. (b) Bar graph results. Columns 
represent normalised peak height ratio of the target amplicon to the reference amplicon calculated for each [taken 
from (Borun et al., 2014)].
Stellenbosch University  https://scholar.sun.ac.za
Stellebosch University https://scholar.sun.ac.za
36 
1.7.4 Next generation sequencing 
Sanger sequencing is considered to be a 'first-generation' sequencing technique, while more 
recent sequencing technologies are referred to as next-generation sequencing (NGS). NGS 
technologies comprise of various strategies that rely on a combination of template preparation, 
sequencing and imaging, genome alignment, assembly methods, and data analysis to produce 
thousands to millions of sequencing reactions at an unparalleled speed (van Dijk et al., 2014). The 
unique combination of specific protocols distinguishes one NGS technology from another, and 
determines the type of data produced from each platform. The general workflow is performed as 
follows: firstly, the source nucleic acid material is converted into a sequencing library. A wide 
variety of NGS library preparation protocols exist, but they all generally fuse fragments of DNA with 
platform-specific adapters. Long DNA molecules are first fragmented into a suitable size (~50–500 
nucleotides) followed by the addition of specialized adapters. A size selection step is then 
performed to enrich further for molecules of the desired size and to eliminate free adapters. Lastly, 
PCR is performed to select for molecules containing adapters at both ends and to generate 
sufficient quantities for sequencing (Figure 1.16).  
Figure 1.16 Simplified representation of a typical NGS library preparation workflow [taken from (van Dijk et al., 
2014)]. 
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Using a variety of imaging techniques and bioinformatics software, a large volume of sequence 
data is processed and subjected to specified analytical software tools to identify putative 
sequence variants in individual DNA samples. However, given the technical limitations of NGS 
technologies, sequencing artefacts are sometimes reported (Metzker, 2010). It is therefore 
necessary to always confirm NGS variants by Sanger sequencing. 
1.7.5 Nomenclature 
In this thesis the nomenclature system for the description of changes in DNA sequences is based 
on that previously described by Antonarakis and the Nomenclature Working Group 
(http://www.dmd.nl/mutnomen.html) (Antonarakis, 1998; den Dunnen and Antonarakis, 2001). 
The term ‘sequence variation’ or ‘variant’ is used to describe sequence variations/changes of 
unknown or unconfirmed protein function. The term ‘polymorphism’ refers to variants found at a 
frequency of ≥1% in the general population. The term ‘mutation’ is used to describe sequence 
changes with confirmed clinical significance or phenotypic consequence. This term is generally 
assigned to variants when there is strong evidence in support of a disease-causing role (e.g. 
evidence of segregation with disease in large pedigrees, and/or laboratory based evidence in 
support of a functional effect on a protein level). 
1.7.6 Online PD databases 
PD databases containing information about genes and genetic variants associated with the 
disease were used extensively in parts of this project. The Mutation Database for Parkinson’s 
disease (MDPD, http://datam.i2r.a-star.edu.sg/mdpd/) (Tang et al., 2009), and the Parkinson 
Disease Mutation database (PDmutDB, http://www.molgen.ua.ac.be/PDmutDB/) were used for 
researching known PD mutations and genetic variants during analysis of sequence data 
(Nuytemans et al., 2010). These databases contain entries from over 1000 of the most recent PD 
publications. 
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1. 8 Aims and objectives of the present study
Given that PD in Black SA patients has been understudied, the aim of the present study was to 
investigate whether these patients have a different genetic aetiology to that reported for other 
PD patients worldwide. To this end, the objectives of the study were to: 
1. Determine whether there are real diagnostic or clinical differences between Black PD patients
and that reported for other SA subpopulation groups.
2. Screen the known PD genes (i.e. parkin, PINK1, DJ-1, ATP13A2, SNCA, LRRK2, VPS35, and
EIF4G1) for disease-causing mutations in this group of patients using Sanger sequencing, high-
resolution melt, multiplex ligation-dependent probe amplification assay and next generation
sequencing techniques.
3. Determine whether Black patients diagnosed with PD harbour pathogenic repeat expansions
at the spinocerebellar ataxia - type 2 (SCA2) and –type 7 (SCA7) loci.
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2.1 Study participants 
This study was approved by the Human Research Ethics Committee at the University of 
Stellenbosch (Protocol number 2002/C059). A total of 147 ethnically-matched control samples 
were recruited from healthy unrelated blood donors from the Blood Donation clinic of the SA 
Western Province Blood Transfusion Service. A total of 47 unrelated PD patients, from the Black SA 
ethnic group, were recruited from the Movement Disorders clinic at Tygerberg Academic Hospital 
in Cape Town (n=32), as well as through a collaboration with a research group from the University 
of Pretoria (n=15). The patients had been examined by movement disorder specialists and met 
the UK Parkinson's Disease Society Brain Bank Research criteria for diagnosis of PD (Gibb and Lees 
1988). The average AAO of the study group was 55.3 years (SD 11.2, ranging from 30 to 77 years). 
Fifteen patients (32%) had disease onset before or at the age of 50 years-old. Twenty-four patients 
(51%) were male. When possible, pedigrees were constructed for selected PD cases (Appendix 
B). Thirty patients (64%) had sporadic PD, 12 (26%) presented with a familial form of the disease 
(i.e. reported a first-, or second-degree relative with PD or PD-related features), and 5 patients 
(11%) had an unknown family history of the disease. The control samples were not clinically 
assessed for any signs of PD and a family history was not taken. A total 57% of the control samples 
were male. As the samples had been ‘de-identified’, no information was available on the ages of 
these controls. 
After obtaining written informed consent from the study participants, peripheral blood samples 
were collected and genomic DNA was extracted. The procedure for the phenol-chloroform DNA 
extraction method is as described by Sambrook and Russell (2006). 
The 47 probands were screened for disease-causing mutations in all the known PD genes using 
various techniques as outlined in Table 2.1. Notably, varying numbers of patients were screened 
with different methods due to varying availability of DNA samples at the time of screening. Initially 
Sanger sequencing was used for mutation screening, but due to the relatively high cost of this 
method, HRM was later used. MLPA was used for detection of CNV changes in all known PD genes, 
and NGS was used towards the end of the study through collaboration with Professor Matthew J. 
Farrer from the University of British Columbia, Canada. 
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Mutation-screening techniques 
Patient ID Sanger sequencing HRM         MLPA NGS 
parkin DJ-1 VPS35 GBA EIF4G1 parkin LRRK2 SNCA 8 known PD genes All known PD genes 
37.12 √ √ √ √ √ ND ND ND √ ND 
42.03 √ √ √ √ √ ND ND ND √ √ 
42.04 √ √ √ √ √ ND ND ND √ √ 
42.56 √ √ √ √ √ ND ND ND √ √ 
43.59 √ √ √ √ √ ND ND ND √ √ 
52.23 √ √ √ √ √ ND ND ND √ √ 
54.74 √ √ √ √ √ ND ND ND √ √ 
55.52 √ √ √ √ √ ND ND ND √ √ 
55.65 √ √ √ √ √ ND ND ND √ √ 
60.39 √ √ √ √ √ ND ND ND √ √ 
60.43 √ √ √ √ √ ND ND ND √ √ 
61.79 √ √ √ √ √ ND ND ND √ √ 
61.81 √ √ √ √ √ ND ND ND √ √ 
63.42 √ √ √ √ √ ND ND ND √ √ 
63.73 √ ND √ √ √ ND ND ND √ √ 
78.74 √ ND √ √ √ ND ND ND √ √ 
84.52 √ √ √ √ √ ND ND ND √ √ 
11.893 ND ND ND ND ND ND ND ND ND ND 
Table 2.1 PD probands screened for disease-causing mutations using different mutation screening techniques. 
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Mutation-screening techniques 
Patient ID Sanger sequencing HRM MLPA NGS 
parkin DJ-1 VPS35 GBA EIF4G1 parkin LRRK2 SNCA 8 known PD genes All known PD genes 
96.87 √ √ ND √ ND ND ND ND √ √ 
10.307 √ √ ND √ ND ND ND ND √ √ 
10.308 √ √ ND √ ND ND ND ND √ √ 
10.309 √ √ ND √ ND ND ND ND √ √ 
10.310 √ √ ND √ ND ND ND ND √ √ 
10.314 √ √ ND √ ND ND ND ND √ ND 
10.317 √ √ ND √ ND ND ND ND √   ND 
11.894 ND ND ND ND ND ND ND ND √   ND 
11.781 ND ND ND ND ND ND ND ND √   ND 
11.793 ND ND √ √ √ √ √   √ √   ND 
11.794 ND ND √ √ √ √ √   √ ND   ND 
11.795 ND ND √ √ √ √ √   √ ND   ND 
11.796 ND ND √ √ √ √ √   √ ND   ND 
11.895 ND ND √ √ √ √ √   √ √   ND 
11.798 ND ND √ √ √ √ √   √ ND   ND 
11.799 ND ND √ √ √ √ √   √ ND   ND 
11.800 ND ND √ √ √ √ √   √ √   ND 
11.801 ND ND √ √ √ √ √   √ ND   ND 
11.802 ND ND √ √ √ √ √   √ ND   ND 
Table 2.1 PD probands screened for disease-causing mutations using different mutation screening techniques. Continued 
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Mutation-screening techniques 
Patient ID Sanger sequencing HRM MLPA NGS 
parkin DJ-1 VPS35 GBA EIF4G1 parkin LRRK2 SNCA 8 known PD genes All known PD genes 
11.803 ND ND √ √ √ √ √   √ ND   ND 
11.804 ND ND √ √ √ √ √   √ ND   ND 
11.805   ND ND √ √ √ √ √   √ √   ND 
11.806   ND ND √ √ √ √ √   √ ND   ND 
11.808   ND ND √ √ √ √ √   √ ND   ND 
11.830   ND ND ND ND ND ND ND   ND √ √ 
11.832   ND ND ND ND ND ND ND   ND √ √ 
11.833   ND ND ND ND ND ND ND   ND √ √ 
11.834   ND ND ND ND ND ND ND   ND √ √ 
11.835   ND ND ND ND ND ND ND   ND √ √ 
ND = not done/ screened as DNA sample was not available at the time of screening, or sample precluded on basis of AAO (some 
genes are a rare cause of PD and limited to young AAO (e.g. GBA), while others such as VPS35 and EIF4G1 are limited to late AAO 
cases). √ = DNA sample was screened using the specified mutation screening technique. 
Table 2.1 PD probands screened for disease-causing mutations using different mutation screening techniques. Continued 
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2.2 Polymerase chain reaction (PCR) and Sanger sequencing 
Polymerase chain reaction (PCR) primers were designed using Primer3 software for each of the 
specified exons of the different PD genes. Primers selected and reaction conditions are detailed 
in Appendix C Table 2.2. PCR reactions were performed in a 2720 Thermal Cycler (Applied 
Biosystems, USA). Each 25μl reaction contained 50ng template genomic DNA, 0.4μM of each 
primer, 75μM dNTPs (Promega, USA), 1.5mM MgCl2, 1X NH4 buffer (Bioline, UK), 5% formamide (for 
selected primer sets) and 0.01U BIOTAQ DNA polymerase (Bioline, UK). PCR conditions comprised 
of an initial denaturation step of 94°C for 5 min, 30 cycles of denaturation at 94°C for 30 s, 
annealing at different temperatures according to each primer set for 30 s, extension at 72°C for 
45 s, and a final extension step of 72°C for 5 min. All PCR reactions performed included a negative 
control to which no DNA template was included (to exclude possible PCR contamination). 
Prior to sequencing, PCR products were cleaned by adding 5U of Exonuclease I (Promega, USA) 
and 0.5U SAP (Shrimp Alkaline Phosphatase) (Cleveland, Ohio, USA) to 8.0μl PCR product. This 
cocktail was then incubated at an initial temperature of 37°C for 15 min followed by 15 min at 
80°C (to denature the enzymes) in a 2720 Thermal Cycler (Applied Biosystems, Foster City, USA).  
The sequencing reaction was performed at the Central Analytical Facility (CAF), Stellenbosch 
University using the Big Dye Terminator Sequence Ready Reaction Kit version 3.1 (Applied 
Biosystems, Foster City, USA). The reactions were electrophoresed and analysed on a 3130 x1 
Genetic Analyser (Applied Biosystems, Foster City, USA). The sequence chromatographs were 
analysed using Sequencher DNA Sequencing Software version 5.1 
(http://www.genecodes.com/). All putative sequence variants were compared against known 
mutations and SNPs found on dbSNP and the Parkinson’s disease mutation databases 
(http://www.thepi.org/parkinson-s-disease-mutation-database/; http://www.pdgene.org/). 
2.3 GBA screening 
Due to the presence of a highly homologous pseudogene (PSGBA), a customised PCR program 
was used to selectively amplify the functional gene (GBA). GBA is longer than PSGBA because of 
several Alu insertions (i.e. defective transposons, lacking the necessary enzyme functions to 
produce a DNA copy of itself) in the intronic tracts of GBA, and a 55-bp deletion in exon 9 of 
PSGBA. However, despite the length difference, PSGBA maintains a 96% sequence identity with 
the functional GBA gene (Figure 2.1). The high degree of sequence identity, and the physical 
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proximity between PSGBA and GBA, facilitates the transcription of the pseudogene, hence the 
need to use a customised PCR program to selectively amplify the functional gene. To this end, 
GBA was amplified as 3 large genomic DNA fragments (a 2972 bp fragment encompassing exons 
1–5; a 2049 bp fragment encompassing exons 6–7 and a 1682 bp fragment encompassing exons 
8–11), using primer sequences provided in Appendix C Table 2.3, and a customized 64°C to 54°C 
touch-down PCR program, summarized in Appendix C Table 2.4. Both exonic and flanking intronic 
regions of GBA were sequenced. A 25μl PCR reaction was performed using 50 ng genomic DNA 
together with 0.4µM forward and reverse primers, 75µM dNTPs, 0.04U/µl DreamTaqTM Green Taq 
polymerase (Fermentas, UK) and 1X Tampon buffer (Bioline, UK). PCR products were purified, 
sequenced and subsequently analysed as described in section 2.2. 
Figure 2.1 Schematic representation of GBA and its homologous pseudogene PSGBA. Exons are depicted as 
boxes with identification numbers inside. Alu sequences are represented as black boxes [taken from (Sorge et al., 
1990; Imai et al., 1993)]. 
2.4  High-resolution melt 
Each 25μl PCR reaction contained 50ng template DNA, 0.4μM of each primer, 75μM dNTPs 
(Promega, USA), 1.5mM MgCl2, 1X NH4 buffer (Bioline, UK), 5% formamide (for selected primer sets) 
and 0.01U BIOTAQ DNA polymerase (Bioline, UK) and 2μM SYTO9 fluorescent dye (Invitrogen, USA). 
Apart from slight deviations in annealing temperature to optimize he amplification of selected 
exons, standard PCR conditions comprised of an initial denaturation step of 94°C for 5 min, 30 
cycles of denaturation at 94°C for 30 s, annealing at 55°C for 30 s, extension at 72°C for 45 s, and 
a final extension step of 72°C for 7 min. HRM analysis was performed from 75 to 95°C, with each 
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successive step rising by 0.1°C using the RotorGene 6000 machine (Corbett Life Science, Australia). 
A negative control was included in each run and samples which exhibited an altered melt profile 
were validated using Sanger sequencing. Where possible, samples with known variants were 
included as positive controls.  
2.5  Multiplex ligation-dependent probe amplification technique (MLPA) 
The MLPA technique was used to detect CNV in the known PD genes. Two commercially available 
probe kits, SALSA P051-C3 and P052-C2 Parkinson MLPA kits (MRC Holland, Amsterdam, The 
Netherlands; http://www.mlpa.com) were used for this assay. Together, the kits consisted of 
probes for all exons of SNCA, parkin, and PINK1, and specific exons of DJ-1 (exons 1, 3, 5, 7), LRRK2 
(exons 1, 2, 10, 15, 27, 41, 49), UCH-L1 (exons 1, 4, 5, 9), and ATP13A2 (exons 2, 9). In addition, several 
probes for CAV1 (exon 3), CAV2 (exon 3), GCH1 (exons 1, 2, 3, 5, 6) and two-point mutations (A30P 
in SNCA and G2019S in LRRK2) were also added as part of the probe kits. Each probe is composed 
of two half-probes (5' and 3' half-probes), consisting of a target-specific sequence and a universal 
primer sequence allowing the simultaneous multiplex PCR amplification of all probes (Schouten et 
al. 2002). All exons of parkin were included in both kits, and the probe sequences of the same exon 
were different between the two kits. The assay was performed for all the samples as outlined in 
Table 2.1, using both kits according to the manufacturer's protocol. 
Initially, 35ng of genomic DNA was denatured at 98ºC for 5 min and then allowed to hybridize to 
the MLPA probe set P051 and P052 (in independent reactions for each probe set). Thereafter, 
ligation was performed at 54ºC for 15 min using a Ligase-65 enzyme. PCR reactions were 
performed in a 2720 Thermal Cycler (Applied Biosystems, Foster City, USA) for 35 cycles (95°C for 
30 s; 60°C for 30 s; 72ºC for 1 min) and a final 20 min step at 72ºC. The primers used for the PCR 
reactions were the SALSA PCR forward primer (labeled) 5′-FAM-GGG TTC CCT AAG GGT TGG A-3′ 
and SALSA PCR reverse primer (unlabeled) 5′-GTG CCA GCA AGATCC AAT CTA GA-3′.The PCR 
products were analysed using a 3130x1 Genetic Analyzer (Applied Biosystems) with GeneScan™-
500LIZ™ size standard (Applied Biosystems). The height or area of the PCR derived fluorescence 
peaks was measured, thereby quantifying the amount of PCR product after normalization. This 
measurement was then compared with that of the control DNA samples in order to determine the 
relative amount of target DNA sequence in the input DNA sample. ABI electopherographs were 
analysed using Coffalyser software version 9.4 (MRC Holland, Amsterdam, The Netherlands; 
http://www.mlpa.com). Possible CNVs were validated using qPCR, and Sanger sequencing.
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2.5.1 Verification of MLPA using qPCR 
Possible CNVs (including exonic deletions or multiplications) detected using Coffalyser software 
version 9.4 (MRC Holland, Amsterdam, The Netherlands; http://www.mlpa.com) were verified by 
performing qPCR using the LightCycler® 96 Real-time PCR system (Roche Diagnostics Corporation, 
Indianapolis, USA), and the LightCycler® FastStart DNA Master PLUS SYBR Green I kit (Roche 
Diagnostics Corporation). qPCR was performed in triplicate for each sample. Each 10μl reaction 
consisted of the following reagents: 2μl Hybridization FastStart Mix (Roche Diagnostics), 0.5μM of 
each primer and 30ng genomic DNA. The PCR conditions were: 95ºC for 10 min, 95ºC for 10 s, 55ºC 
for 10 s, 72ºC for 15 s (45 cycles). The β-globin gene (HBB) was used as the reference gene (i.e. 
internal standard) for subsequent calculations (e.g. normalization of results). Results were analysed 
using the LightCycler® 96 Genetic Variation Analysis Software version 1.5 (Roche Diagnostics; 
Randburg; South Africa; www.roche-diagnostics). 
2.6 Targeted resequencing using next generation sequencing 
A customized target-capture panel covering the exonic regions of 168 major genes which were 
either linked or associated with PD, dementia, and related neurodegenerative conditions was 
designed by our collaborator Professor Matthew J. Farrer from the University of British Columbia, 
Canada (Appendix D. Table 2.5). Genomic DNA was sheared to 150bp using the Covaris® E220 
sonicator and enriched for exonic regions of interest according to the TargetSeqTM Custom 
Enrichment Kit protocol (Life Technologies, Carlsbad, CA, USA). Quantification and quality control 
was performed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) and a 
Qubit Fluorometer (Life Technologies). Captured DNA was then amplified by bead emulsion PCR 
with the EZ Bead system (Life Technologies) and sequenced on a SOLiD 5500xl platform (Life 
Technologies).  
Mapping, sequence alignment, duplicate removal, SNP calling and indel detection were 
performed by Lifescope version 2.5.1 (Life Technologies). Annotation was performed with 
ANNOVAR (Wang, Li, and Hakonarson 2010) using hg19 as the reference genome. The latter 
includes a normalized conservation score from the UCSC Genome Browser (Karolchik et al., 2014), 
PHAST PhyloP (http://compgen.bscb.cornell.edu/phast/), as well as prediction scores from 
sequence homology–based programs Sorting Intolerant from Tolerant (SIFT) (Sim et al., 2012), 
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), and MutationTaster 
(http://www.mutationtaster.org/). Ethnically-matched control data was extracted from the 1000 
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Genomes Project (ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/release/20110521/) and the 
NHLBI Exome Sequencing Project (ESP; http://evs.gs.washington.edu/EVS/) and then compared. 
The frequency of genetic variants observed was subsequently compared with Black control 
subjects (n = 48). Sanger sequencing was used to validate the NGS results, and customized primers 
were designed for this purpose (Appendix E. Table 2.6). 
2.6.1 in silico functional predictions programs 
In silico predictive methods were used to predict the potential of each amino acid substitution to 
impact protein structure and activity. Three predictive programs, namely: SIFT, PolyPhen-2, and 
MutationTaster were used concurrently, to compensate for the unique limitations of each 
program. The basis of these respective programs is sequence conservation over evolutionary time, 
the physical and chemical properties of the exchanged residues, and the protein structural 
domain information. It is not uncommon to get different functional predictions for the same variant 
when using these programs, as each uses a unique algorithm which forms an integral part of its 
predictive score. Functional predictions of the variants identified using NGS and validated using 
Sanger sequencing, were determined using the tolerance scores summarized in Appendix F Table 
2.7. 
2.7 Screening for repeat expansions at the SCA2 and SCA7 loci 
Automated fluorescent genotyping of the SCA loci was performed using the ABI PRISM 3100xl 
Genetic Analyzer (Applied Biosystems). This approach was used due to the limitations of 
conventional capillary electrophoresis (CE). A definitive repeat expansion cannot be determined 
using CE due to the existence of polymorphisms within the SCA primer-binding sites which may 
result in the preferential amplification of a single allele which may either represent two normal 
alleles of the same size (homozygous), or a single normal allele with a second allele expanded 
beyond the range of detection. To circumvent these limitations, the fluorescent tandem repeat-
primed PCR (TP-PCR) assay was used to specifically amplify large repeat expansions at the SCA 
loci. The TP-PCR assay was first described by Warner et al. (1996) to replace Southern blotting as a 
means of detecting hyperexpansions of trinucleotide repeat sequences. TP-PCR usually consists of 
three primers (Figure 2.2): a forward primer that is fluorescently labelled and flanks the repeat 
region (TPF), a repeat primer that is complementary to the targeted repeat but carries a 
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nonspecific tail sequence (TP-R1), and a third primer that is identical to the nonspecific tail 
sequence (TP-R2). The tail primer is designed to prevent progressive shortening of the amplicons 
during PCR cycling, thereby producing a characteristic peak profile of increasing length. This 
profile enables the rapid identification of large pathogenic CAG repeats that cannot be amplified 
using primers that flank the repeat region due to size limitations with conventional PCR. However, 
the main drawback of TP-PCR is that it does not enable the repeat number to be accurately 
determined. 
Figure 2.2 Positions of three primers used in the TP-PCR assay. This assay facilitated the rapid detection of CAG 
expansions in exon 3 of SCA7. The asterisk indicates the fluorescently-labelled forward primer. 
TP-PCR was performed according to a protocol kindly provided by Ms Danielle Smith (Division 
Human Genetics, University of Cape Town), which was adapted from Majounie et al. (2007). Primer 
sequences used for SCA7- TP-PCR were as follows:  
Locus-specific primer (Forward primer) 5′-FAM-CCCAGCATCACTTCAGGACT-3′, repeat-specific 
primer 5′-TACGCATCCCAGTTTGAGACGCAGCAGCAGCAGCAGCAGCAG-3′, and a tail primer 
5′-TACGCATCCCAGTTTGAGACG-3′. TP-PCR assay was performed in a reaction volume of 25 μl 
containing 50 ng genomic DNA, 0.01U GoTaq in 1X GoTaq buffer (Promega), 75μM dNTPs 
(Promega, USA), 5% DMSO, 5M Betaine (Promega, USA ), 0.4μM of each primer (TPF, TP-R1, and TP-
R2). A SCA7 positive control, consisting of 57 CAG repeats was included in the assay. The reactions 
were subjected to 30 PCR cycles consisting of 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 
30 seconds followed by a 10 minute extension at 72°C. All PCR products were analysed by capillary 
electrophoresis on the ABI 3130x1 Genetic Analyzer. The GeneScan™ Rox500 size standard was 
used for HEX-labelled PCR products, and the GeneScan™ LIZ250 size standard was used for FAM-
labelled PCR products (Applied Biosystems). Results were analysed using GeneMapper® software, 
version 4.1 (Applied Biosystems). Positive control samples were included with each assay (SCA7-
positive control with 54 CAG repeats). 
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In order to size the CAG repeat expansions in exon 1 at the SCA2 loci, the following forward and 
reverse primers were used: 5′-56-FAM-AGGAGACCGAGGACGAGGAC-3′ and 5′-
GCGTGCGAGCCGGTGTAT-3 respectively. Primers flanking the SCA2 CAG repeat were designed 
for this purpose (Figure 2.3).  
Figure 2.3 Positions of primers flanking the SCA2 CAG repeat. These primers facilitated the detection of CAG 
expansions in exon 1 of SCA2, and the sizing of the repeat expansion. The asterisk indicates the fluorescently-
labelled forward primer. 
The PCR products were amplified using the following PCR program: 96°C for 5min; followed by 30 
cycles of 96ºC for 30 seconds, 50°C for 15 seconds and 60°C for 4min, with 5% formamide as an 
additive in the PCR reaction. All PCR products were analysed by capillary electrophoresis on the 
ABI 3130x1 Genetic Analyzer as described for SCA7. Result were analysed as described for SCA7. 
2. 8 Agarose gel electrophoresis 
In order to confirm successful amplification of the appropriate DNA target, PCR products were run 
on agarose gels containing ethidium bromide (EtBr), which intercalates DNA molecules and allows 
for visualisation under UV light. For a 2% agarose gel, 2g of agarose powder was dissolved in 100ml 
1X SB buffer and heated in a 950 Watts microwave at maximum heat for 2.5 min. Following a short 
cooling phase, 0.35µg/ml EtBr was added to liquid agarose, which was subsequently left to set in 
a gel mould for 20 minutes. 2μl PCR product was mixed with 2μl Cresol® loading dye. 2μl of the 
Gene Ruler 100bp DNA Ladder (Fermentas International Inc., Canada) was loaded into the first 
well. The gel was run at 120 Volts until the loading dye had reached the bottom of its respective 
column. Following electrophoresis, the gel was visualized under UV-light, using the UVIPro Gel 
Documentation System (UVITec, UK). A PCR product was considered to have been successfully 
amplified if only one well defined band was visible. A negative control, consisting of standard PCR 
mix and sterilised water instead of template DNA, was included in each electrophoretic run.
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3.1 Clinical characteristics of patients 
Of the total 47 Black PD patients recruited for this study, fifteen were referred from the University of 
Pretoria where they were diagnosed by Professor Clara Schutte and Dr. Celia Mahne. The 
remaining thirty-two patients were recruited from the Movement Disorders Clinic at the Tygerberg 
Academic Hospital in Cape Town, where they were diagnosed by consulting Movement disorder 
specialists Professor Jonathan Carr and Dr. Percy Kumire. The clinical examination of these patients 
included a standardized questionnaire for demographic data collection and detailed 
neurological examination. The definition of the syndrome of PD was based on UK Parkinson's 
Disease Society Brain Bank Research criteria for diagnosis of PD, as described by Gibb and Lees 
(1988).  
Overall, no real diagnostic or clinical differences were reported between Black PD patients, and 
that reported for other SA subpopulation groups. These observations were based on a 
comprehensive clinical evaluation of each patient, and each patient’s response to L-DOPA 
treatment. Due to cost-constraints, neuroimaging (brain computerised tomographic scan and 
magnetic resonance imaging) was only available for two patients, neither of whom were 
considered to be remarkable or distinctly different from other PD patients from different SA ethnic 
groups. It can therefore be suggested that Black PD patients cannot be distinguished from other 
ethnic populations solely based on their clinical profile.  
3.2 Screening of parkin, DJ-1, GBA, VPS35, EIF4G1, SNCA and LRRK2 using Sanger sequencing and 
HRM 
In this study all exons of parkin (exons 1-12), DJ-1 (exons 1-7) and GBA (exons 1-11) were screened. 
Only selective exons were screened in the following genes: VPS35 (exon 15), EIF4G1 (exon 23), 
SNCA (exon 2, and 3), and LRRK2 (exon 32, and 41), as common disease-causing mutations have 
only been previously identified in these specific exons.  
The previously described G430D heterozygous mutation in exon 12 of parkin (Haylett et al., 2012) 
was verified in the present study (Figure 3.1). No additional mutations in parkin were identified, but 
a number of polymorphisms were found (Table 3.1). Notably, all the sequences were aligned using 
the NCBI Human Reference Genome NCBI36/hg18. 
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 Patient 37.12 (G>A) 
Figure 3.1 Sequence chromatogram indicating the position of the heterozygous G430D (1429 G>A) mutation in 
parkin exon 12.  
The heterozygous G430D mutation was found in a female proband (78.74) with AAO of 56 years. 
This mutation is found in the parkin RING2 domain which is known to mediate the enzymatic 
catalytic activity.  
To assess the structural change resulting from the glycine to aspartic acid change at position 430 
(G430D), the structural information was obtained from the Protein Data Bank –file 4I1H 
(http://pdb.rcsb.org/pdb/explore/explore.do?structureId=4I1H), and annotations about this 
protein were obtained from Uniprot-entry PRKN2_HUMAN 
(http://www.uniprot.org/uniprot/O60260). Figure 3.2 illustrates the amino acid structural change 
from a wild-type to a mutant amino acid. The mutant residue introduces a charge in a buried 
residue which may lead to alterations in protein folding. 
Figure 3.2 Predicted structural change resulting from the heterozygous G430D (glycine to aspartic acid) mutation 
in parkin exon 12. 
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The mutant and wild-type amino acid residues are distinctly different. Predictive algorithms such 
as PolyPhen-2 have predicted this amino acid change to be ‘possibly damaging’ on a functional 
level, because this change occurs in the RING2 domain, a region that is evolutionarily conserved 
across a number of species. 
Common polymorphisms were classified as sequence variants if they were found at a frequency 
of ≥1% in the general population, and these were identified using various public databases 
including The UCSC Genome browser (http://genome.ucsc.edu), the Mutation Database for 
Parkinson’s disease (http://datam.i2r.a-star.edu.sg/mdpd/index.php), the international HapMap 
project (http://pngu.mgh.harvard.edu/~purcell/plink/res.shtml#hapmap), and dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/). 
Table 3.1 Sequence variants found throughout the genomic region of parkin. 
Previously described mutations are highlighted in red. Common polymorphisms are highlighted in blue. Novel 
sequence variants identified in the present study are highlighted in black. 
Patient  ID Sequence variants 
37.12 IVS2+ 20 C>T, IVS8 -21_-17del 
42.03 IVS8+48C>T 
42.04 IVS2+ 20 C>T,  IVS4+75T>A 
42.56 IVS2+ 20 C>T, R402C 
43.59 IVS8+48C>T, V380L, IVS4+91C>A 
52.23 IVS2+ 20 C>T 
55.52 IVS2+ 20 C>T, L261L, V380L, IVS4+91C>A 
55.65 IVS2+ 20 C>T, IVS4+ 75T>A, IVS8 -21_-17de 
60.39 IVS2+ 20 C>T, P37P 
60.43 V380L, D394N, IVS2-18 T>A 
61.79 VS2+ 20 C>T, V380L 
61.81 M192L, V380L 
63.42 IVS2+ 20 C>T, P37P, IVS4+91 C>A 
63.73 IVS2+ 20 C>T, P37P, C238C, IVS+91 C>A 
78.74 G430D 
96.87 IVS2+ 20 C>T, P37P, C238C, 3΄UTR+16G>A 
10.307 IVS8+48C>T, IVS4+ 75T>A 
10.308 M192L, IVS8+48C>T 
10.309 C238C , L261L, M192L Homo C , IVS4+ 75T>A 
10.310 IVS4+ 75T>A 
10.314 IVS8+48C>T, V380L, IVS4+ 75T>A 
10.317 IVS2+ 20 C>T, P37P, C238C, IVS4+ 75T>A 
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Similarly, no pathogenic mutations were identified in DJ-1, VPS35, EIF4G1 and GBA (Table 3.2). 
Table 3.2 Sequence variants identified in DJ-1, GBA, and selective exons of VPS35 and EIF4G1. 
ND= not done/screened as the DNA sample was unavailable at the time of screening. Common variants are 
highlighted in blue. Novel sequence variants identified in the present study are highlighted in black. (-)= no variants 
were found in the specified patient. 
 Sequence variants 
Patient ID DJ-1 GBA VPS35 EIF4G1 
37.12 A56T - H579H - 
42.04 IVS1+84C>T,  IVS4-98 G>A - - - 
42.56 G78G  ,   IVS2-109 C>T - - - 
43.59 G78G T369M - - 
52.23 IVS2-109 C>T - - - 
54.74 IVS2-109C>T - - - 
55.52 IVS4-98 G>A, IVS6+32A>G - - - 
55.65 IVS5-31C>T, IVS6+32A>G - - - 
60.39 IVS4-98 G>A T369M - - 
60.43 IVS5-31C>T, IVS6+32A>G - - 
61.79 IVS5-31C>T,  IVS4-98 G>A - - - 
63.42 IVS1+37G>A,  G78G - - - 
84.52 IVS4-98 G>A - - - 
11.793 ND ND H579H - 
11.794 ND ND H579H - 
11.795 ND ND H579H - 
11.796 ND ND H579H - 
11.895 ND ND H579H - 
11.798 ND ND H579H - 
11.799 ND ND H579H - 
11.800 ND ND H579H - 
11.801 ND ND H579H - 
11.802 ND ND H579H - 
11.803 ND ND - R1223H 
11.804 ND ND H579H - 
11. 806 ND ND H579H - 
11.808 ND ND H579H - 
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Common polymorphisms in DJ-1 (A56T), and GBA (T369M), were identified in three unrelated 
patients (Figure 3.3). 
Patient 37.12 (A56T)  Patient 43.59, and 60.39 (T369M) 
Figure 3.3 Sequence chromatographs indicating the position of the common polymorphisms found in exon 5 of DJ-
1 (529 G>T) (37.12), and exon 2 of GBA (745 C>T) (43.59, and 60.39). 
Due to the high cost of Sanger sequencing, HRM was used as an alternative screening method. 
Figure 3.4 illustrates the use of HRM technique as a mutation screening method. The inclusion of 
positive control samples harbouring known mutations proved to be successful in distinguishing 
between wild-type samples and mutation-positive samples.  
Using HRM to screen exons 2 and 3 of SNCA, and exons 31and 41 of LRRK2, no pathogenic 
mutations, or polymorphisms were detected. 
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Figure 3.4 HRM difference graph indicating the G2019S variant in LRRK2 exon 41 (used as a positive control), 
distinguished from the patient samples which are all wild-type. Normalized fluorescence subtracted from a reference 
sample is plotted on the y-axis and temperature in degrees Celsius is plotted on the x-axis. 
3.3 Screening for copy number variation 
CNVs were identified in two of the six known PD genes included in the MLPA assay, these results 
are summarized in Table 3.3. 
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Table 3.3 Potential heterozygous CNVs identified in MLPA probe mixes. 
Patient ID Mix 1 (P051-C3) Mix 2 (P052-C2) Verified using qPCR 
37.12 PARK2 ex2 Dup, PARK2 ex9 Del − ✔ 
61.81 PARK2 ex5 Del − ✕ 
10.307 PINK1 ex1 Del; SNCA ex5 Del − ✕ 
10.308 PARK2 ex5 Del - ✕ 
10.309 SNCA, ex4,5,6,7 Dup PARK2 ex4, ex9 Dup ✕ 
Previously described CNV highlighted in blue. Dup = duplication, Del = deletion, ex = exon. Novel CNVs identified 
in the present study are highlighted in black. ✔ indicates that the CNV was confirmed using qPCR, and X indicates 
that the CNV could not be confirmed as ‘real’ using qPCR. 
No CNV was detected in the following PD causing genes included the MLPA assay: PINK1, DJ-1, 
LRRK2, and ATP13A2. The putative CNVs found in SNCA could not be verified using qPCR, 
because the amplification curves of the wild-type controls were not consistent across several 
runs, resulting in off-target amplification. The PCR products were run on an agarose gel, and 
revealed non-specific binding, which resulted in primer dimer formation. Further optimisation is 
required and a SNCA specific qPCR primer assay will need to be designed, and a variety of 
chemical additives (e.g. DMSO, formamide, or Betaine) will also be used as these may 
significantly minimize or eliminate non-specific amplification when performing a qPCR assay. 
Figure 3.5 Graphical representation of previously described parkin exon 2 duplication, and exon 9 
deletion identified in patient 37.12 by Keyser et al. (2010). Notably, probes for all exons of parkin 
are distributed across the two probmixes (i.e. Mix 1 P051-C3 and Mix 2 P052-C2), the same CNV 
should therefore be identified in both mixes to be considered for further assessment of potential 
pathogenicity on a functional level. 
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Figure 3.5 Graphical representing of possible CNVs in two unrelated patients. The light blue columns represents 
wild type sample, dark blue column represents the patient sample with a possible parkin exon 9 duplication, red 
columns represents the patient sample with a possible parkin exon 2 duplication, and exon 9 deletion. Columns 
represent the normalised peak height ratio of the target amplicon to the reference amplicon as calculated for each 
sample. The normalized ratio is plotted on the y-axis. The gene of interest and exonic region is plotted on the x-
axis. 
When one of the exons of the analysed gene undergoes a deletion, its peak height decreases 
and, at the same time, the peak height of the reference amplicon increases (as seen for 37.12, 
exon 9 deletion, red column). The situation is reversed in the case of duplication, with the peak of 
the reference amplicon decreasing and the peak of the analysed amplicon increasing (as seen 
for 37.12, exon 2 duplication, red column). In order to observe these differences, the results are 
compared with control DNA samples. The CNV identified in patient 10.309 was found to be a false-
positive using qPCR, it was therefore concluded that this patient did not harbour the parkin exon 
9 duplication. 
The parkin exon 5 deletion could not be confirmed using qPCR. This was expected, as this possible 
CNV is generally considered to be a false positive, due to the presence of a M192L polymorphism 
in exon 5 which results in a single-base change that alters the binding site of the probes for exon 5 
of parkin in MLPA kit P051-C3. This false positive CNV was identified in two unrelated patients, 61.81 
and 10.308. Sequencing of the region to which the MLPA probes bound, did indeed confirm that 
both these patients harbour the M192L polymorphism (Figure 3.6), which affects the binding of the 
exon 5 probes for MLPA kit P051-C3. 
Stellenbosch University  https://scholar.sun.ac.za
Stellebosch University https://scholar.sun.ac.za
60 
  Patients 10.308 and 61.81 (A>C) 
Figure 3.6 Sequence chromatograph confirming the presence of the M192L polymorphism found in the two patients 
with the false positive deletion in parkin exon 5. 
3.4 NGS Analysis 
NGS was used to screen all known PD-causing genes as well as 160 other genes involved in 
neurodegenerative diseases in 22 patients. A stepwise filtering approach was used to prioritize the 
list of variants, and these variants were then compared to those found in various public databases. 
Selective variants were confirmed using Sanger sequencing, and the frequency thereof was 
subsequently determined by screening a group of ethnic matched controls (n = 99). The following 
criteria were used to prioritize variants generated from the NGS panel:  
1. Synonymous variants and common polymorphisms found in public databases such as dbSNP,
1000 Genomes Project and the Exome Sequencing Project (ESP) were excluded.
2. Only variants identified in patients, and not in controls were prioritized.
3. Only variants implicated in PD or Dementia were included. Dementia is a common feature of
PD with disease progression.
4. Variants with a minor allele frequency (MAF) greater than 0.03% were excluded. The cut-off
frequency was based on estimates of the global PD incidence, ranging between 3 and 22
per 100,000 person-years for all age groups (Muangpaisan et al. 2011).
Using the above criteria, a prioritized list of 15 sequence variants in 10 genes was compiled (Table 
3.4). These were selected from an initial list of 98 sequence variants in 35 genes in both patients 
and controls. Using Sanger sequencing, 13 variants were validated, while the variants found in 
MAPT and ATP13A2 were found to be false-positives.
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Table 3.4 List of prioritised sequence variants identified using high-throughput targeted resequencing. 
Variants highlight in red = previously reported pathogenic mutations, blue = common variants, black = sequence variants not previously described in literature. 1kG 
MAF= 1000 Genomes project minor allele frequency of variants, ESP EA MAF = minor allele frequency of variants in European American populations, ESP AA MAF 
= minor allele frequency of variants in African American populations. AA = amino acid change. √ indicates that variants were validated using Sanger sequencing (SS)
Patient ID rsID Gene UCSC Exon AA Change Disease dbSNP 1kG MAF ESP EA MAF ESP AA MAF Validated by SS 
61.81 novel   ATP13A2 Exon 22 S811R Kufor-Rakeb, PD NA 0 NA NA x 
55.65 rs112725508   DCTN1 Exon 8 P209R ALS, FTD, PD NA 0 NA NA √ 
60.43 rs112868112   DNAJC13 Exon 44 E1740D Dementia, PD NA 0 NA NA √ 
96.87 rs121908301   GBA Exon 12 G517R Dementia, PD NA 0 NA NA √ 
54.74 novel   LRRK2 Exon 16 I610T PD NA 0 NA NA √ 
61.81 novel   LRRK2 Exon 36 H1758P PD NA 0 NA NA √ 
84.52 novel   LRRK2 Exon 44 N2133S PD NA 0 NA NA √ 
52.23 novel   LRRK2 Exon 49 T2423S PD NA 0 NA NA √ 
10.308 novel   MAPT Exon 11 L550P FTD, PD NA 0 NA NA x 
78.74 rs191486604   PARK2 Exon 12 G430D PD 0 0 0.000349 0 √ 
54.74 rs137853055   PARK2 Exon 8 Q311K PD 0 0 NA NA √ 
10.308,10.309, 
61.81 
rs115477764   PINK1 Exon 7 E476K PD 0.00011 0.009 0 0.042896 √ 
10.307 rs63751071   PSEN1 Exon 5 I143M Dementia NA 0 NA 0 √ 
61.81 rs112451138   PSEN1 Exon 7 V191A Dementia NA 0 NA 0 √ 
10.310 Not assigned   PSEN2 Exon 6 V139M Dementia NA 0 0.000116 0 √
Table 2.3 Sequence variants identified in selective genes. Continued. 
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Three in silico functional predictive programs, namely SIFT, PolyPhen-2, and MutationTaster were concurrently used to predict the 
potential impact each amino acid substitution may potentially have on the function of the encoded protein. These functional 
predictions are summarized in Table 3.5. 
Table 3.5 in silico functional predictions, based on amino acid substitutions of variants found in the respective genes. 
PolyPhen-2 predictions with an asterisk should be interpreted with caution, as the protein alignment did not have enough sequence diversity for the algorithm 
to give a confident score. SIFT (LC) predictions= low confidence (i.e. the protein alignment does not have enough sequence diversity). NV (not valid) = transcript 
has several partial isoforms. 
Only classifications which were consistent across all three predictive programs were considered to be of high confidence. Consistent 
predictions could not be made for the 4 LRRK2 novel variants using SIFT and PolyPhen-2, possibly because annotation of these variants 
was performed with ANNOVAR using GRCh37/hg19 as the reference genome (performed by Professor Matthew Farrer), whereas the 
publically available predictive programs currently are still using the NCBI36/hg18 reference genome from March 2006 (available at 
http://genome.ucsc.edu). 
Gene Exonic region AA change SIFT prediction PolyPhen 2 prediction MutationTaster prediction Concordance across 
all three programs 
DCTN1 Exon 8 P209R Tolerated Benign Polymorphism Yes 
DNAJC13 Exon 44 E1740D Intolerant (LC) Benign* Polymorphism No 
GBA Exon 12 G517R Tolerant Benign Polymorphism Yes 
LRRK2 Exon 16 I610T NV NV Polymorphism No 
LRRK2 Exon 36 H1758P NV NV Polymorphism No 
LRRK2 Exon 44 N2133S NV NV Disease causing No 
LRRK2 Exon 49 T2423S NV NV Polymorphism No 
PARK2 Exon 12 G430D Intolerant Probably damaging Disease causing Yes 
PARK2 Exon 8 Q311K Intolerant Probably damaging Disease causing Yes 
PINK1 Exon 7 E476K Tolerated Benign Polymorphism Yes 
PSEN1 Exon 5 I143M Intolerant Probably damaging Disease causing Yes 
PSEN1 Exon 7 V191A Intolerant Probably damaging Disease causing Yes 
PSEN2 Exon 6 V139M Intolerant (LC) Benign* Polymorphism Yes 
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3.4.1  Known pathogenic mutations 
Of the 13 variants confirmed using Sanger sequencing, I143M, and V191A (Figure 3.7 and Figure 
3.8) were of interest given that these variants are listed as 2 of more than 150 mutations shown to 
be causal for early-onset familial Alzheimer’s disease (AD) (http://www.molgen.vib-
ua.be/ADMutations/). These mutations are found in exon 5 and 7 respectively, in the gene 
encoding for presenilin-1 (PSEN1). The I143M mutation is thought to alter the way in which the 
amyloid precursor protein is cleaved, this alteration results in aggregation of the protein in the 
brain, leading to nigral damage, and the development of AD. In the present study, the I143M 
mutation was found in one male proband with AAO of 44 years (10.307), and V191A mutation was 
found in another male proband with AAO of 55 years (61.81). These variants were found to be 
evolutionarily-conserved across different species, and predicted to be pathogenic by all three 
functional predictive algorithms (Figure 3.7 and Figure 3.8). However, to the best of our knowledge, 
neither of these patients have been clinically diagnosed with AD, nor do they have a known family 
history of the disease (personal communication, Dr. Kumire). 
 I143M variant 
Zebrafish PFREDTETVGQRALHSMLNAIIMISVIVVMTLVLVVLYKYRCYKVIQAWLFFSNLLLLFF 
AC frog PFTEDTESVGQRALNSILNATIMISVIIVMTILLVVLYKYRCYKVIHGWLIISSLLLLFF 
Cattle PFTEDTETVAQRALHSILNAVIMISVIVIMTILLVVLYKYRCYKVIHAWLIVSSLLLLFF 
Human PFTEDTETVGQRALHSILNAAIMISVIVVMTILLVVLYKYRCYKVIHAWLIISSLLLLFF 
Mouse PFTEDTETVGQRALHSILNAAIMISVIVIMTILLVVLYKYRCYKVIHAWLIISSLLLLFF 
** ****:*.****.*:*** ******::**::*************:.**:.*.****** 
Figure 3.7 (A) Sequence chromatograph of a proband with the I143M (425 G>T), variant in exon 5 of PSEN1 (B) 
Sequence alignments of I143M in Zebrafish (NP_571099.1), African clawed (AC) frog (AAH77762.1), cattle 
(AAI51459.1), human (NP_000012.1), and mouse (AAH30409.1). The highlighted amino acids indicate the position 
of the I143M variant. The conserved amino acids are indicated by asterisk. 
A 
B 
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 V191A variant 
Zebrafish FSLIYLGEVFKTYNVAMDYFTLALIIWNFGVVGMICIHWKGPLRLQQAYLIMISALMALV 
AC frog FSYIYLGEVFKTYNVAVDYITLALLIWNFGVVGMICIHWKGPLLLQQAYLIMISALMALV 
Cattle FSFIYLGEVFKTYNVAMDYISVALLIWNFGVVGMIAIHWKGPLRLQQAYLIMISALMALV 
Human FSFIYLGEVFKTYNVAVDYITVALLIWNFGVVGMISIHWKGPLRLQQAYLIMISALMALV 
Mouse FSFIYLGEVFKTYNVAVDYVTVALLIWNFGVVGMIAIHWKGPLRLQQAYLIMISALMALV 
** *************:**.::**:**********.******* **************** 
Figure 3.8 (A) Sequence chromatograph of a proband with the V191A (571 C>T) variant in exon 7 of PSEN1. (B) 
Sequence alignments of V191A in Zebrafish (NP_571099.1), African clawed (AC) frog (AAH77762.1), cattle 
(AAI51459.1), human (NP_000012.1), and mouse (AAH30409.1). The highlighted amino acids indicate the position 
of the V191A variant. The conserved amino acids are indicated by asterisk. 
3.4.2 HRM screening in ethnically-matched controls 
The frequency of the prioritized variants was determined in 99 Black SA controls. Only the DNAJC13 
E1740D variant was found in a control at a frequency of 1.0%. The variant was easily distinguished 
using HRM (Figure 3.9). As observed from the normalized melt curve, the sample with the E1740D 
variant has a different melt curve profile to that of the wild-type control samples. However, the 
melt profile of the positive control is identical to that of the E1740D-positive sample.  
The presence of the E1740D variant was verified in one control sample using Sanger sequencing 
(Figure 3.10). 
B 
A 
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Figure 3.9 HRM normalized graph illustration of the E1740D variant indicating that the sample harbouring the 
variant can be distinguished from the wild-type. Normalized fluorescence subtracted from a reference sample is 
plotted on the y-axis and temperature in degrees Celsius is plotted on the x-axis. 
Figure 3.10 Sequence alignment generated using BioEdit. Sequence alignment of the positive sample, a control 
sample found to be positive for the E1740D variant in exon 44 of DNAJC13, and three WT samples. The position 
of the E1740D variant is indicated by the red arrow.  
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3.5 Repeat expansions at the SCA7 and SCA2 loci. 
3.5.1 SCA7 
To genotype the CAG repeats at the SCA7 locus, the DNA samples of all 47 Black PD patients 
were successfully amplified using TP-PCR (Figure 3.11). 
Figure 3.11 SCA7 exon 3 fragments amplified by PCR. The PCR products were loaded on a 1.5% agarose gel, 
resolved for 1 hour at 100V in 1X SB buffer and stained with 0.35µg/ml EtBr. The photographs were taken after 
exposure to UV light. A 100bp molecular weight marker was loaded in the first lane (M) of each gel, with the 
100bp and 500bp band indicated. Lanes 1 to 8 represents the different patient samples, with the negative control 
loaded in lane 9.  
Genotyping of the PCR products was subsequently performed using the ABI 3130xl Genetic 
Analyzer, which facilitated distinction between patients with a normal SCA7 profile (<19 CAG 
repeats), and those harbouring CAG repeats, which fall within the pathogenic expanded range 
(>33 repeats). The size standard GeneScan™ LIZ250 was used to analyse the electropherogram 
peaks using GeneMapper software. All samples were genotyped on at least two separate 
occasions. A positive control with 57 CAG repeats was also included in the ABI analysis for 
comparative purposes (Figure 3.12 A). Of the 47 patients screened, 45 had a SCA7 profile which 
was similar to that of a wild-type sample (Figure 3.12 B). 
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A. Positive control with a pathogenic peak profile 
 B. Patient with a normal repeat peak profile 
Figure 3.12 Electropherograms of SCA7 profiles. (A) The peak profiles show a gradually descending array of 
peaks, characteristic of a positive control with a repeat expansion in the pathogenic range. (B) Characteristic peak 
profile of an individual with a repeat expansion in the normal range (SCA7 negative). Numerical values on the x-
axis denote the product size (in bp), and the y-axis denotes arbitrary units of fluorescence intensity. 
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The SCA7 profile for two unrelated male patients was observed to be atypical (Figure 3.13), and 
may be indicative of a CAG repeat expansion which falls within the intermediate range (i.e. 28-
35 CAG repeats). 
A. Patient 11.798 
B. Patient 11.799 
Figure 3.13 Electropherograms of two patients with an atypical SCA7 profile. 
Further genetic analysis of the two patients were undertaken in order to clarify their SCA7 status.
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Figure 3.14 illustrates that the HRM technique could be effectively utilized to distinguish the positive control sample harbouring the 57 
CAG repeats (pathogenic range) from the patients who were shown to have the atypical SCA7 peak profile (Figure 3.13 A and B), and 
the wild-type samples. From the HRM melt curve profile, it can be deduced that patients 11.799 and 11.798 do not harbour SCA7 repeats 
which fall within the pathogenic range, as their melt profiles were clearly distinguishable from that of the positive control. 
Figure 3.14 HRM curve exhibiting the melt profile of the positive control, from that of patient 11.799, 11.798 and samples which are all wild-type. Normalized 
fluorescence subtracted from the reference sample is plotted on the y-axis, and the temperature in degree celsius is plotted on the x-axis.
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3.5.2 SCA2 
Exon 1 of the SCA2 locus was successfully amplified in all 47 Black patients by PCR (Figure 3.15) 
Figure 3.15 SCA2 exon 1 fragment amplified by PCR. The PCR products were loaded on a 1.0% agarose gel, 
resolved for 30 minutes at 120V in 1X SB buffer and stained with 0.35µg/ml EtBr. The gel photographs were taken 
after exposure to UV light. A 200 bp molecular weight marker was loaded in the first lane (M), with the 200bp and 
1kb band indicated. Lanes 2 to 11 represents the different patient samples, with the negative control loaded in lane 
12.  
Genotyping of the PCR products was subsequently performed using the ABI 3130xl Genetic 
Analyzer, which facilitated distinction between alleles in the normal range (14 to 30 repeats) and 
those in the pathogenic expanded range (34 to 77 repeats) using the the size standard 
GeneScan™ LIZ250. All samples were genotyped on at least two separate occasions.  
Figure 3.16 (A) shows the ABI profile of a patient who is homozygous for 22 CAG repeats, and 
Figure 3.16 (B) shows the ABI profile of a patient who is heterozygous for the same number of 
repeats at the SCA2 locus. 
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A. Patient 60.39 
B.  Patient 55.65 
Figure 3.16 ABI SCA2 genotypic profiles. Peak profiles could be distinctly classified as (A) homozygous or (B), 
heterozygous based on each individuals electopherograph profile.  
In order to accurately size the CAG repeats at the SCA2 locus, two patients with homozygous 
profiles were selected for sequencing, the PCR products were amplified using an unlabelled 
primer pair identical to that previously used to genotype the repeats using the ABI Genetic 
Analyzer.  
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The sequence chromatograph of one individual (who was found to harbour 22 repeats at the SCA2 locus, Figure 3.17) was then used 
as a basis to calculate the repeat length for all the other patients using GeneMapper® software.  
Figure 3.17 Sequence chromatogram of a patient harbouring 22 CAG repeats, which falls within the normal range of repeats in exon1 of the SCA2 locus. 
None of the patients harboured a pathogenic repeat expansion at the SCA2 locus. All 47 patients screened were found to have a 
SCA2 repeat length which falls within the normal range (i.e. 14-30 CAG repeats). It was determined that 22 repeats were the most 
common number of repeats among the 94 chromosomes screened as illustrated in Figure 3.18. Twenty-two repeats were present at a 
frequency of 68% (64/94). 
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Figure 3.18 Graphic representation of the number of repeats in the SCA2 gene in the 47 Black PD patients. 
Twenty-one chromosomes were found to have 23 repeats at the SCA2 locus (22.3%), 7 
chromosomes had 29 repeats (7.4%), which is the largest number of repeats identified in this 
group of patients, while 20 repeats were found at the lowest frequency (2.1%), with only two 
chromosomes having this number of repeats at the SCA2 locus. 
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4.1 General discussion 
A growing body of studies thus far have comprehensively reported on the genetic aetiology 
of PD. However, most have targeted the European, North-American and East-Asian 
populations (Dahodwala et al., 2009). Genetic studies on the SSA populations, especially those 
of Black African ancestry remain almost totally underrepresented, or unexplored in some 
countries (Blanckenberg et al., 2013; Pringsheim et al., 2014). This is a significant shortcoming 
given that there is strong evidence to suggest that SSA populations have the highest degree 
of genetic diversity, compared to other populations, and it is thought that this genotypic and 
phenotypic diversity may even exist within the same population group (Tishkoff et al., 2009).  
To the best of our knowledge, the present study is the first report on the molecular genetic basis 
of PD in the Black SA ethnic group. Moreover, this is the first comprehensive analysis of all known 
PD genes: SNCA, LRRK2, EIF4G1, VPS35, parkin, PINK1, DJ-1, and ATP13A2 in this population to 
date. Common disease-causing mutations were not detected using a variety of mutation 
screening techniques. It is therefore possible that other, still unknown genetic determinants or 
novel genes for PD may account for the disorder in this population group. Two patients carrying 
previously described parkin mutations were verified in the present study. However, no 
mutations were found in the remaining PD causing genes in any of the other patients screened. 
Given the unique ancestry of the Black SSA population, it is possible that PD disease-causing 
genes found in other ethnic populations worldwide, may not contribute to the disease 
aetiology in this group of patients. Although this study represents the largest Black SA PD cohort 
screened to date (n=47), it is necessary to screen a larger cohort in order to obtain a more 
representative, and accurate estimate of the frequency of PD mutations which may be 
attributable to the Black SA population. 
The genetic aetiology of PD is thought to be distinctly different across the various ethnic 
population groups worldwide (Van Den Eeden et al., 2003; Wright Willis et al., 2010). A case-in-
point is the LRRK2 G2019S mutation in exon 41 which has been found in 30–40% of familial and 
sporadic PD patients from North Africa, and 10–30% of Ashkenazi Jews (Lesage et al., 2006; 
Ozelius et al., 2006). About 0-2% of PD patients in other countries carry this mutation, but G2019S 
has never been reported in a single Black patient to date (Guedes et al., 2010; Bardien et al., 
2011). Okubadejo and colleagues performed a study in which fifty-seven Nigerian patients with 
sporadic PD were screened, this included sequencing of LRRK2 exon 31 and exon 41, all parkin 
exons, as well as repeat expansions at the SCA3 locus (Okubadejo et al., 2008). No pathogenic 
mutations were identified in any of these genes. Another study also sequenced LRRK2 exon 31 
and exon 41 in a Black Ghanaian PD cohort consisting of fifty-four patients, once again, no 
pathogenic mutations were detected (Cilia et al., 2012). Similar results have also been found 
in a study by Yonova-Doing et al. (2012) in which thirty-eight Zambian patients were screened 
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for all exons of SNCA, LRRK2, parkin, PINK1, and DJ-1 using Sanger sequencing, and MLPA 
analysis of parkin, PINK1, DJ-1, LRRK2, and SNCA was also performed. A common limitation 
encountered in all of these studies is that of a small patient sample size. Nevertheless, studies 
performed thus far, concur that further genetic screening of Black PD patients is warranted, 
given that the majority of cases screened to date cannot be attributed to known PD genes.  
Relatively few epidemiologic studies on PD in African countries have been published so far, 
thus the real prevalence of this disorder in this region is still unclear. However, populations are 
undergoing a demographic transition which is characterized by an increase in mean life 
expectancy (Dotchin et al., 2012). Population ageing is a common trend in developed 
countries where the largest proportion of elderly people currently resides (Sanderson and 
Scherbov, 2014). However, this trend has only recently been described in SSA populations, with 
the latest projections suggesting that the gap in life expectancy between SSA and the world 
average will drop to 10 years by 2050, from nearly 20 years in 2010 (Dorsey et al., 2007; 
Sanderson and Scherbov, 2014). As life expectancy continues to increase, age-related 
disorders such as PD are expected to become increasingly common, particularly given the 
current lack of preventative therapy, predictive markers, or a cure for the disease. Given the 
scarcity of genetic studies on PD in SSA populations and the expected rise in the incidence of 
this disease in these populations, the aim of the present study was to determine the genetic 
aetiology of PD in a group of Black SA patients.  
In the first part of the study, a description of the current clinical profile of thirty-two individuals 
was documented as provided by consulting Neurologist Professor Jonathan Carr and Dr. Percy 
Kumire from the Movement Disorders Clinic at Tygerberg Academic Hospital. A systemic 
analysis was performed to assess if there is any appreciable clinical variation between these 
and other SA PD patients of different ethnicities. Overall, the clinical profile of PD in Black SA 
patients was considered to be similar to that of other population groups, although young-onset 
cases were less commonly encountered, and the frequency of a positive family history was 
lower than that reported for White SA PD groups. However, such differences could be 
attributed to ascertainment biases. 
In the genetic part of the study, the patients were screened for known PD mutations in parkin, 
DJ-1, EIF4G1, VPS35, LRRK2, SNCA, and GBA using Sanger sequencing and HRM. The Sanger 
sequencing biochemistry is considered ‘gold-standard’ as a mutation screening technique 
given its ability to achieve read-lengths of up to 1,000 bp with a potential detection accuracy 
of 99.999% (van Dijk et al., 2014). The heterozygous G430D mutation which was found in one of 
our patients was initially described by Sun et al. (2006), and later described by Haylett et al. 
(2012) in a separate study by our group. In the latter study, the G430D mutation was found in 
two unrelated patients of different ethnic backgrounds (i.e. Black and White) with an AAO of 
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56 and 27 years respectively, each harbouring the G430D mutation, in addition to an exon 4 
deletion in parkin (Haylett et al., 2012). Sequence variants were classified as polymorphisms if 
the variant had a minor allele frequency of ≥ 1% across various public databases without known 
association to disease, was located in a non-coding region, or resulted in a synonymous 
change. All of the polymorphisms identified in the present study, have been described 
previously in the SA population in separate studies by our group (Bardien et al., 2009; Keyser et 
al., 2010; Haylett et al., 2012). These include: six non-synonymous variants (M192L, V380L, R402C, 
G235V, S167N and D394N), three synonymous variants (P37P, L261L, and C238C), and two 
intronic variants (IVS2 +25T>C, IVS8+48C>T) found throughout the parkin genomic region. In 
addition, five novel intronic variants were found in the present study (IVS4+75T>A, IVS4+91C>A, 
IVS4 +75T>A, IVS4 +100C>A, IVS4 +101G>C). Taken together, we did not find parkin mutations 
to confer a major contribution to disease in the current patient group; only 1 out of the 24 
patients screened using Sanger sequencing were found to have pathogenic mutations. In 
contrast, previous studies of numerous PD families of different ethnic backgrounds worldwide 
have demonstrated a considerable contribution of parkin mutations to early-onset (≤50 years) 
PD forms ( Lücking et al., 2000; Hedrich et al., 2004). This difference may possibly be attributed 
to the AAO of our patient cohort. Of the patients screened in the present study using Sanger 
sequencing, 38% (9/24) had an AAO of less than 50 years (range 30-49). It is possible, as 
demonstrated in several studies, that the frequency of parkin mutations decreases significantly 
with increasing age at disease onset (i.e. occurs in nearly 80% of individuals with AAO before 
age 20, and <25% in those with onset after 50 years of age) (Periquet et al., 2003; Hedrich et 
al., 2004). The low frequency of parkin mutations in our study cohort could therefore be partially 
attributed to the late age of disease onset for the majority of the patients screened (i.e. 62.5%, 
15/24), who had an AAO of between 50 and 74 years, or due to the fact that these patients 
harboured mutations in other genes. 
 
Mutations in DJ-1 are the least common of all known causes of ARPD forms (<1% of early-onset 
PD) (Sironi et al., 2013). It was therefore not surprising that no novel or known pathogenic 
mutations were identified in DJ-1. Furthermore, six intronic variants, one non-synonymous (A56T), 
and one synonymous (G78G) polymorphism were found throughout the genomic region of DJ-
1 in the 22 patients screened in this part of the study.  
 
Two patients were found to harbour a non-synonymous polymorphism in GBA (T369M). This 
polymorphism was previously classified as a mutation by Beutler et al. (1996), but later found to 
be a common polymorphism in 1.1% of 126 PD patients, and in 1.5% of 210 controls screened 
(Walker et al., 2003). This polymorphism has also been shown to be a minor risk factor for PD in 
a multicentre study which screened PD patients from North America, Europe, and Australia 
(Nalls et al., 2013). The allelic frequency of the T369M polymorphism was found to be marginally 
higher in controls than in PD patients [(odds ratio) OR = 6.97, 95% (confidence interval) CI 0.93–
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52.02; P = 0.03], which was consistent with findings from other multicentre studies (Lesage et al., 
2011; Pankratz et al., 2012).  
 
No pathogenic mutations or sequence variants were found in EIF4G1 or VPS35. It is however 
possible that some mutations could have been missed as only the two previously described 
R1205H and D620N mutations in EIF4G1 and VPS35, respectively, were screened for, while the 
entire gene was screened in the case of parkin, DJ-1 and GBA. However, to date no other 
mutations have been reported in the other exons of these two genes. 
 
No mutations or novel variants were found in the patients who were screened for exons 2 and 
3 of SNCA, and exons 31 and 41 of LRRK2. Screening the entire LRRK2 gene, consisting of 51 
exons, was not cost-effective given the fact that the most frequent pathogenic mutations have 
only been found in these two exons. Nearly 80 LRRK2 variants have been reported worldwide, 
but proven pathogenicity has only been demonstrated for seven mutations (Ross et al., 2011). 
Four of these mutations are found in exon 31 (N1437H, R1441G, R1441G, and R1441GH), one in 
exon 35 (Y1699C, has only been found in one family from the United Kingdom), and two are 
found in exon 41 (G2019S, and I2020T) (Paisán-Ruíz et al., 2004). Similarly, patients were only 
screened for mutations in two exons of SNCA, as only four mutations in SNCA have been shown 
to contribute to disease pathogenesis: one in exon 2 (A53T), and three in exon 3 (A30P, E46K 
and G51D) (Golbe et al., 1990; Papadimitriou et al., 1999). The pathogenicity of the most 
recently identified H50Q mutation (Proukakis et al., 2013) in exon 4 of SNCA had not been 
proven at the time of screening, this exon had thus been excluded for mutation screening. 
Notably, the lack of mutations found cannot be attributed to the mutation screening 
technique, as positive controls were included in the HRM analysis, and this approach has been 
successful in detection of a number of variants across patient and control samples in previous 
studies by our group (Keyser et al., 2010; Glanzmann et al., 2014).  
 
In the present study, one patient was found to harbour CNV mutations: a parkin gene deletion 
of exon 9 and a duplication of exon 2. This had previously been reported by another study by 
our group (Keyser et al., 2010). However, these CNV variants were independently confirmed in 
the present study using qPCR (Figure 3.5). Moreover, the parkin exon 5 deletion identified in two 
patients using MLPA was shown to be a false positive result using qPCR and Sanger sequencing. 
These patients (i.e. 61.81, and 10.308) were shown to have the M192L polymorphism (Figure 3.6) 
which is located at the annealing site of the MLPA P051-C3 kit’s probes for parkin exon 5, the 
presence of which resulted in the false positive signal compatible with a heterozygous deletion 
of parkin exon 5. Notably, no other CNVs were detected in the remaining PD genes included 
in the MLPA kits (i.e. SNCA, PINK1, DJ-1, LRRK2, and ATP13A2).  
 
Stellenbosch University  https://scholar.sun.ac.za
79 
 
Using a targeted resequencing approach, 22 patients were screened using a custom-made 
gene panel covering the exonic regions of 168 major genes (Appendix C Table 2.5) which are 
either linked or associated with PD and related neurodegenerative conditions. Targeted 
resequencing, is a high-throughput mutation screening approach which falls under the 
second-generation arm of next generation sequencing technologies (van Dijk et al., 2014). To 
avoid the challenges associated with whole genome sequencing, a more focused targeted 
resequencing approach was used as this technique offers a powerful, cost-effective 
alternative which facilitates in-depth interrogation of the genomic regions of interest (Chasman 
and Adams, 2001; Sim et al., 2012). Additionally, targeted resequencing allows for increased 
focus of the genomic regions most likely to provide relevant data, thereby increasing the 
chances of finding biologically relevant variants or mutations (Li et al., 2014). The mutation-
screening efficiency of the targeted resequencing approach has previously been 
demonstrated in numerous studies (Hodges et al., 2007; Rivas et al., 2011; Lin et al., 2012). 
 
In the present study, targeted resequencing yielded a prioritised list of 15 non-synonymous 
sequence variants in 10 genes (Table 3.4), which were selected for further analysis. The validity 
of 13 out of 15 variants was confirmed using Sanger sequencing, while two were shown to be 
false-positives. Three unrelated patients each harboured an identical PINK1 polymorphism 
(E476K), which has been shown to decrease mitochondrial membrane potential under 
oxidative stress conditions (Rogaeva et al., 2004; Kawajiri et al., 2011), but further studies are 
warranted to prove its pathogenicity. For the other sequence variants identified; the potential 
functional effect was assessed using computational predictive tools SIFT, PolyPhen-2, and 
MutationTaster as summarized in Table 3.5. In silico methods were utilised in an effort to predict 
the potential impact the sequence variants could potentially have on protein function with the 
hope of using this knowledge to select candidate genes for future functional studies. The ability 
of these in silico tools to predict the potential of amino acid substitutions to impact protein 
structure and activity relies on factors which are important to protein function, including but 
not limited to, sequence similarity and homology, conservation over evolutionary time, 
secondary structure, solvent accessibility, polarity, side chain volume, and surface area 
accessibility (Chasman and Adams, 2001; Sim et al., 2012). Three different programs were used, 
as each one uses a different predictive algorithm, which highlights certain protein 
characteristics, while omitting others. For example, SIFT predictive scores are based on the 
sequence homology among related genes (Ng and Henikoff, 2001), while PolyPhen-2 
incorporates the sequence conservation, the molecular characteristics of the amino acid 
residues involved, and the secondary structural features of the protein using the annotated 
protein database, SwissProt (Sunyaev et al., 2001). MutationTaster is considered to be 
comparatively more reliable given that SIFT and PolyPhen-2 predictions are restricted to 
homologous sequences that are available in the protein database, while MutationTaster uses 
a naïve Bayes classifier which enables the software to give predictions for novel variants, and 
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genes which are not fully annotated or available in protein databases (Wu and Jiang, 2013). 
Of the 13 confirmed sequence variants, tolerance predictions for 8 (61.5%) variants were 
consistent across the three programs Table 3.5. Functional predictions for the 4 novel variants 
found in LRRK2 could only be obtained using MutationTaster, and predictive scores were 
inconsistent for the DNAJC13 variant E1740D, which may be attributed to the existence of 
several partial isoforms of the gene. Previously described parkin mutations, Q311K and G430D 
were accurately classified as disease-causing across the three programs. The Q311K mutation 
which is located between the first really interesting new gene (RING1) finger domain and the 
in-between-RING (IBR) domain, has been shown to cause reduced ubiquitin modification, 
while the G430D mutation (located in the second RING finger domain, RING2), has been shown 
to alter the solubility and localization of the protein in a functional study performed in SH-SY5Y 
cells (Sriram et al., 2005). However, it should be noted that for the individual harbouring the 
Q311K variant, a second pathogenic mutation in parkin was not found. Parkin-related PD is 
generally thought to be early-onset, but interestingly, both mutations in the present study (i.e. 
G430D, and Q311K) were found in two unrelated patients both of whom had late onset PD (56 
and 63 years of age, respectively). However, it is possible that these patients may have 
developed the disease at an earlier age, but were clinically diagnosed only at a much later 
stage. This is indeed conceivable given that these patients reside in the rural Eastern Cape, 
with little or no access to a Movement disorder specialist.  
 
The I143M variant in PSEN1 was consistently predicted to be disease-causing across the three 
programs. This variant has previously been shown to co-segregate with disease in a large SA 
family of Black African ancestry, with early AD (Heckmann et al., 2004). All of the mutations in 
the presenilin genes (i.e. PSEN1 and PSEN2) are dominantly inherited (i.e. one mutant allele is 
sufficient to cause the carrier to develop AD). However, the consulting clinicians in this study 
have stated that the patient harbouring the PSEN1 I143M mutation does not have AD, but may 
suffer from severe dementia. Such a case is however possible, as there has indeed been reports 
of disease-causing mutations that show incomplete penetrance, even for Mendelian diseases. 
A case in point is the age-dependent penetrance of the LRRK2 G2019S mutation which varies 
considerably in different PD populations. In a study of 126 at-risk family members of probands 
from Cantabria Spain, the G2019S mutation was shown to have a penetrance of 28% at age 
59 years, 51% at age 69 years, and 74% at age 79 years (Sierra et al., 2011). This reduced 
penetrance is considerable even in PD patients from Cantabria, who have amongst the 
highest reported frequency of G2019S mutations reported so far after North African Arabs and 
Ashkenazi Jews (Guedes et al., 2010; Sierra et al., 2011). One may thus suggest that unique 
modifier genes or other features of the genetic background may strongly influence the 
phenotypic expression of disease-causing mutations. 
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The novel LRRK2 variant N2133S was classified as ‘disease-causing’, while the other three 
(H1758P, T2423S and I610T) were classified as ‘polymorphisms’ using MutationTaster. These 
variants were found in four separate individuals with AAO ranging from 50 to 63 years, which is 
typical of the late PD AAO (50 years and older) usually associated with LRRK2. Using the SMART 
Protein Analyzer (http://smart.embl-heidelberg.de/), it was determined that these variants are 
found in the COOH-terminal WD40 domain (N2133S), the kinase domain (T2423S), the COR 
(COOH terminal of Roc) domain (H1758P), and between the ARM (Armadillo) and ANK (ankyrin 
repeat) domain (I610T). The functional significance of these sequence variants remains to be 
established.  
 
The use of targeted resequencing allowed for the simultaneous selection of many target 
regions across multiple samples, and provided an effective solution for maximizing high-
throughput mutation-screening. The frequency of the 13 prioritised variants was obtained from 
controls which were extracted from the 1000 Genomes Project (ftp://ftp-
trace.ncbi.nih.gov/1000genomes/ftp/release/20110521/), the NHLBI Exome Sequencing 
Project (ESP; http://evs.gs.washington.edu/EVS/), and dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/). Furthermore, the frequency of these variants was 
screened in 147 (99 with HRM and 48 with NGS) ethnically-matched SA Black controls. Only 1 
out of the 13 sequence variants was found in 1 control (Figure 3. 9), which was confirmed using 
Sanger sequencing (Figure 3. 10). This DNAJC13 E1740D sequence variant was classified as a 
‘polymorphism’ by MutationTaster, with conflicting predictions from SIFT and PolyPhen-2 (Table 
3.5). This discordance across the three in silico programs may be because the gene has not 
been fully annotated, and several isoforms currently exist of its protein domains. Therefore, the 
functional significance of the E1740D sequence variant remains to be established.  
 
The high-throughput targeted resequencing approach has facilitated the screening of the 
entire coding regions of all known PD genes as well as 160 other genes associated with related 
neurological conditions (i.e. Alzheimer’s disease, Kufor-Rakeb, and Dementia). At the time of 
the study 22 of the patients were analysed using this approach, the remaining 25 patients will 
be screened in the coming months.  
 
SCA7 represents the most common SCA subtype in the SA population, and is due to a 
pathogenic CAG expansion in the ataxin-7 protein (Zander et al., 2001). It has since became 
clear from a study by Scholefield et al. (2009) that a common founder haplotype surrounding 
the SCA7 region explains the exclusive detection of SCA7 in the Black SA population group. 
Given the exclusive existence of this founder event in this population group, and the similar 
pathogenic mechanism utilised by ataxin-7 and α-synuclein to impair the ALP in SCA7 and PD, 
respectively, it was of interest to determine if our study group had pathogenic repeat 
expansions at the SCA7 locus.  
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Using the repeat-primed PCR with fluorescently-labelled primers, the wild-type SCA7 profile was 
easily distinguishable from that of the positive control with a repeat expansion (Figure 3.12 A). 
However, due to the limitations of this approach, the accurate size of the SCA7 repeat length 
in each patient could not be determined. Using this approach, an atypical expansion profile 
was detected in two PD patients (Figure 3.13, A and B). These patients have a profile which is 
neither typical of the wild-type or the positive control which harbours 57 CAG repeats. It is 
possible that these patients (11.798 and 11.799) contain a CAG repeat length which falls within 
the reduced penetrance range (i.e. 34 to 35 repeats). However, using HRM these two patients’ 
melt profiles were more similar to the wild-type than the positive control (Figure 3.14) indicating 
that they probably do not harbour pathogenic expansions. All of the other patients had repeat 
profiles that looked like that of a wild-type sample. 
 
Pure PD symptoms (i.e. resting tremor, bradykinesia, rigidity), with excellent response to L-DOPA 
therapy have previously been described in patients, harbouring pathogenic repeat expansions 
at the SCA2 locus (Gwinn-Hardy et al., 2000). Misdiagnosis of SCA2 patients with PD is not 
uncommon given the number of overlapping phenotypic features shared by the two 
movement disorders (Ragothaman et al., 2004; Socal et al., 2009). What is more, parkin (the 
most frequent cause of ARPD) has been shown to regulate the intracellular levels of both wild-
type and mutant ataxin-2 (Huynh et al., 2007). Given the links between SCA2 and PD, the length 
of the CAG repeat expansions at the SCA2 locus was determined in the current PD group and 
compared with that described for other PD patients worldwide. Moreover, this was a unique 
opportunity to assess whether SCA2 repeat expansions could potentially form part of the 
genetic aetiology of this group of patients. 
 
The CAG repeat length at the SCA2 locus was determined in all 47 patients. Analysis using 
GeneMapper® software revealed that all these patients had a repeat length which fell within 
the normal range (i.e. 14 to 30 repeats). Twenty-two was found to be the most frequent number 
of repeats in 64 chromosomes (68%), while 23 repeats were found at a frequency of 22.3% in 
the 94 chromosomes screened (Figure 3.18). Our findings are in agreement with previous 
findings in various ethnic populations worldwide, including: French (Imbert et al., 1996), 
Japanese (Mizushima et al., 1999), Indian (Choudhry et al., 2001), and Polish (Sobczak, 2004) 
populations, where 22 CAG repeats was found to be the most common repeat length in the 
majority of PD patients screened. Twenty-nine (7 chromosomes) and 20 repeats (2 
chromosomes) were the highest and lowest number of CAG repeats, respectively found in the 
present study. However, 29 repeats is the most frequent repeat length in European and 
Japanese populations (Takano et al., 1998). Notably, the sequence chromatographs of two 
patients who were homozygous for 22 CAG repeats revealed the presence of a single CAA 
interruption (Figure 3.17). This is not uncommon, patients with PD, or parkinsonism often have 
shorter CAG repeat lengths, in addition to one or more CAA interruptions which are thought to 
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stabilise the repeat, thereby limiting further repeat expansion (Furtado et al., 2002; Kim et al., 
2007). Moreover, the CAA interruption is thought to stabilise the mutant ataxin-2 protein in 
selective neurons (Lu et al., 2004). Taken together, results from the present study may suggest 
that repeat expansions at the SCA2 locus do not confer a genetic contribution to PD in this 
group of patients, nor is it a modifier for the disorder. However, a larger patient group is 
necessary to substantiate the aforementioned results in a more representative sample size. 
 
4.2 Study limitations 
 
4.2.1 Study participants 
 
Limitations of the present study included the rather small number of study participants (n = 47) 
from the Black ethnic group. We initially started the screening analysis with a total group of 24 
patients; it was only towards the latter part of the study that we were able to secure 47 patients 
for mutation screening. However, despite extensive efforts, additional patients could not be 
recruited for this study. This may be due to ascertainment biases, the diagnostic criteria applied, 
different population aging dynamics, and a general lack of awareness of the disease owing 
to the scarcity of published literature, particularly in the native languages spoken by the millions 
of South Africans residing in the rural areas where access to education is frequently inadequate 
(Mshana et al., 2011; Dotchin and Walker, 2012).  
 
It was also difficult to follow-up on most of our patients (i.e. to get further information, or 
rebleeds when necessary), as many were from the rural regions of the Eastern Cape, and could 
therefore not be reached. A further compounding limitation in this study, was the relatively few 
number of patients who had one or more affected family members (n = 5, 11 %). It was 
therefore difficult to determine the pathogenicity of novel variants as co-segregation with 
disease within a family could not be assessed. Whether this is reflective of a true difference in 
PD susceptibility in these populations, the unique genetic diversity of this ethnic group or due 
to ascertainment bias is still unclear. 
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4.2.2 Limitations of mutation screening techniques 
 
4.2.2.1 High-resolution melt 
 
Although heterozygote detection using HRM is relatively good in our experience, data from 
two independent studies suggest that the misclassification risk is about 10% (Montgomery et al., 
2007; Wittwer, 2009). HRM accuracy is highly dependent on the PCR product length, with more 
errors or misclassification being evident as the length increases above 400 bp (Reed and 
Wittwer, 2004; Erali and Wittwer, 2010). Moreover, different saturating DNA dyes are variably 
effective. For example, LC Green® Plus is thought to detect heterozygotes better than SYTO® 9 
(which was used in the present study) which detect heterozygotes better than EvaGreen®, 
which is much better than SYBR® Green I (Lyon and Wittwer, 2009). Although most single base 
pair changes can be successfully genotyped using HRM, the homozygous genotype of 
selective variants, resulting from a single base pair change, can be difficult to detect at times, 
even under the best instrumental and experimental conditions (Montgomery et al., 2007; 
Gundry et al., 2008).  
 
4.2.2.2 Multiplex-ligation dependent probe amplification 
 
MLPA analysis was used in this study to screen for large deletions/duplications in the known PD 
genes, because of its effectiveness in detecting homo- and heterozygous CNV in a multiplex 
manner. The MLPA technique is potentially prone to false positive results as seen with the M192L 
polymorphism in MLPA probe mix P051-C3 (Scarciolla et al., 2007). Therefore, confirmation of 
all exonic deletions/duplications should be performed using techniques such qPCR, southern 
blotting, long range PCR, fluorescence in situ hybridization (FISH), or Sanger sequencing to 
exclude false-positives. The MLPA technique is also very sensitive to contaminants (e.g. high salt 
concentrations, and PCR inhibitors such as small remnants of phenol), which can result in 
aberrant peak profiles. Although MLPA results are reported to be reliable with only 20ng DNA, 
in our experience we found that 35–50 ng is required for reliable and reproducible results. MLPA 
is also more sensitive to the method used for DNA extraction (e.g. phenol–chloroform 
extraction, ethanol precipitation, or spin column-based nucleic acid), and also to DNA 
degradation than conventional PCR (Scarciolla et al., 2007; Keyser et al., 2010).  
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4.2.2.3 High-throughput targeted resequencing 
 
The advantages of second-generation sequencing technologies are currently offset by several 
disadvantages. The most prominent of which includes the read-length (which is currently much 
shorter than conventional sequencing for all of the new platforms), and the raw accuracy (on 
average, base-calls generated by the new platforms are nearly tenfold less accurate than 
base-calls generated by Sanger sequencing) (Liu et al., 2012). The 22 patients screened by 
NGS in the present study were screened using the SOLiD 5500xl platform which has certain 
limitations to its high-throughput capacity. Although the SOLiD sequencing platform is widely 
claimed to have 99.94% accuracy (Liu et al., 2012), it has the shortest reads (maximum of 75 
nucleotides) of all the sequencing platforms, and relatively long run times (van Dijk et al., 2014). 
Moreover, the SOLiD platforms panel of sample preparation kits and services is less well 
developed and less widely used than the Illumina MiSeq, Ion Torrent, and Pacific Biosciences 
sequencing platforms. As a comparison, sequencing datasets generated using Illumina MiSeq, 
Ion Torrent, SOLID platform, and Pacific Biosciences sequencing platforms were shown to 
demonstrate error rates of <0.4%, 1.78%, 3–5%, and 13%, respectively (Bansal, 2010; Quail et al., 
2012). Therefore, all the sequence variants identified using these NGS technologies must be 
confirmed by Sanger sequencing, because of the tendency of these methods to detect false 
positives.  
 
4.2.2.4 in silico functional predictive tools 
 
Computational tools, being in silico methods, are not 100% accurate. Flanagan and colleagues 
assessed the utility of various in silico bioinformatic tools in a diagnostic setting, and found that 
the sensitivity of SIFT and PolyPhen-2 was reasonably high (69% and 68%, respectively), but their 
specificity was low (13% and 16%) (Flanagan et al., 2010). Moreover, both programs were found 
to be significantly better at predicting loss-of-function mutations than gain-of-function 
mutations (Flanagan et al., 2010). In a separate study in 2013, Frousios et al evaluated the utility 
of SIFT, PolyPhen-2, and MutationTaster compared to nine other in silico programs and found 
MutationTaster to have the highest sensitivity and specificity rate (88% and 92%, respectively) 
(Frousios et al., 2013). The predictions of these tools should thus be interpreted with caution and 
further evidence to support/refute pathogenicity should be sought before reporting novel 
changes. Three important criteria have to be fulfilled in order to accurately infer the 
pathogenicity of a sequencing variant, namely: (i) co-segregation of the variant with the 
disease, (ii) absence of the variation in healthy age and ethnic matched group, and (iii) 
evidence of a biological role of the mutated protein either using in vitro and/or in vivo models 
(Meeus et a., 2010).  
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4.3 Future work 
 
The continued recruitment of Black PD patients will be instrumental for future studies, preferably 
those with young AAO as they are more likely to have a genetic predisposition. However, 
patients with late-age of disease onset will not be excluded as mutations in LRRK2 have been 
found in late onset PD cases, with both familial and sporadic forms of the disease (Bonifati, 
2007; Nuytemans et al., 2010). Additionally, mutations in VPS35, and EIF4G1have only been 
found in late onset PD cases (Trinh et al., 2014). The present study identified a number of known 
SNPs and novel variants from the comprehensive screening of all known PD genes. Apart from 
the previously identified parkin CNVs (duplication of exon 2 and deletion of exon 9) in one Black 
PD patient (Keyser et al., 2010), the parkin mutations in another patient (G430D and deletion 
of exon 4) (Haylett et al., 2012), and the parkin exon 8 mutation (Q311K) identified in the present 
study, no pathogenic mutations were identified in any of the remaining seven known PD genes 
screened. It can therefore be deduced that the causative genes in the remaining 44 patients 
may either be due to a novel mutation in a known PD gene, or a new PD-causing gene. For 
this reason, from the list of 13 confirmed variants, one novel variant in a known PD gene could 
be selected as a possible candidate for future functional studies, possibly the N2133S variant 
found in exon 44 of LRRK2. This variant may be of interest, because it is located in the WD40 
domain, disruption of which has been shown to result in abolished dimer formation, impaired 
kinase activity, and aberrant protein localization (Jorgensen et al., 2009). Several variants have 
been described in this domain, two of which have been identified as risk factors for sporadic 
PD (T2356I and G2385R) (Cardona et al., 2014). Results from a study by Rudenko and colleagues 
suggests that the LRRK2 WD40 domain plays an important role in maintaining the enzymatic 
function of the protein (Rudenko et al., 2012). Therefore, the N2133S variant should be 
investigated further, using functional experimental approaches to gain better insights into the 
functionality of this variant. One may attempt to demonstrate changes in gene/protein 
expression, or kinase activity relative to the wild-type protein using a cell model in SH-SY5Y 
neuroblastoma cells. 
 
The DNAJC13 E1740D variant would also be an ideal candidate for future functional studies, 
because it was previously identified in one individual from a Northern Kalahari Bushman 
population (African region not specified, dbSNP version 141, rs112868112), and it was found in 
only one control in the present study. However, DNAJC13 has several incomplete transcripts, 
and its protein functional domains have not been fully characterized, further research is thus 
still needed to fully annotate, and prove the putative role of this gene in PD pathogenesis. 
 
For SCA2 genotyping, all 47 patients should be Sanger sequenced in order to accurately 
determine whether or not the CAA interruption found in the two patients sequenced in this 
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study is common to the entire group, and also to determine whether the position of this 
interruption varies between patients.  
 
Efforts should be made to design PCR primers spanning the SCA7 repeat region in order to 
accurately determine the number of repeats in each individual, similar to what was done for 
the SCA2 locus. However, conventional PCR for SCA7 has had limited success (personal 
communication, Danielle Smith, UCT). Southern blotting is currently one of the available sizing 
strategies that can be used for this purpose. However, this approach is technically demanding, 
and may prove costly for the purpose of screening the 47 patients. Another sizing approach, 
which specifically facilitates the screening of expanded CAG repeats is small pool PCR (SP-
PCR), as described by Nakamura et al. (2001). This is a highly sensitive PCR assay used for the 
detection of low levels of repeat expansions. This approach may be ideal given that all 47 
patients in our cohort were shown to not have an expanded repeat profile using the ABI 
Genetic Analyzer and HRM.  
 
Furthermore, genome-wide SNP microarrays should be used to detect regions of homozygosity 
(ROH) throughout the genome of the 47 PD patients. Depending on the genomic context, ROH 
may indicate ancestral homozygosity, uniparental disomy (i.e. when an individual receives two 
copies of a chromosome, or part of a chromosome from one parent and no copies from the 
other parent), or parental consanguinity (i.e. a union between two individuals who are related 
as second cousins or closer) (Alkuraya, 2010; Kearney et al., 2011). Short ROH (less than 5Mb) 
are considered to be ancestral markers of an outbred population (i.e. when offspring from 
crosses between individuals from different populations have lower fitness than offspring from 
crosses between individuals from the same population) (Gibson et al., 2006). The presence of 
a single, or several large ROH on the same chromosome most likely indicates uniparental 
disomy, especially if the ROH is telomeric (i.e. located near the telomere region) (Papenhausen 
et al., 2011). Multiple large ROH spread across different chromosomes is representative of a 
parental blood relationship (McQuillan et al., 2008). This approach may help to identify a 
common novel disease-causing mutation for PD shared by the 47 patients, and may further 
suggest descent from a common ancestor (i.e. that the patients are ancestrally related). 
 
Whole-exome sequencing (WES) is another plausible strategy to pursue. WES is an NGS 
technology that exclusively looks at the “exome”, which consists of all the genome’s exons (i.e. 
the coding portions of genes - these are the regions that get translated, or expressed as 
proteins). Two families (8 and 15, Appendix B) who were found to have no known PD causing 
mutations would be ideal candidates for WES because the DNA of at least two affected 
individuals is available for mutation screening, per family. Moreover, WES would be instrumental 
in identifying a novel PD gene which may account for the disorder in these families. WES is 
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essentially an abridged version of the more complete, but extremely costly, whole genome 
sequencing. Instead of targeting 3 billion base pairs of the human genome, exome sequencing 
focuses on the DNA segments that code for proteins (i.e. exons, approximately 1.2% ), which 
have previously been shown to harbour over 85% of all disease-mutations and many disease-
predisposing SNPs throughout the genome (Botstein and Risch, 2003). Once a patient’s DNA is 
extracted and the exons sequenced, computer programs identify sequence variants in the 
patients DNA, in comparison to a reference sequence of the human genome. It is envisaged 
that identification, and subsequent verification of these variants may pin point a rare, or novel 
genetic variant which may be causative for PD in families 8 and 15. 
 
4.4 Conclusions 
 
This study is the first mutation screening report of all known PD genes, exclusively in the Black SA 
population. No pathogenic mutations were found in the gene most commonly known to cause 
PD in European populations (e.g. LRRK2 G2019S). However, given the rather small size of the 
cohort studied, definite conclusions regarding variant frequencies cannot be made. However, 
this study represents the first comprehensive screening of all known PD genes in a sub-Saharan 
African population, which in itself is a noteworthy achievement. We report here that two 
previously described parkin mutations (i.e. G430D, and Q311K) were found to be a negligible 
cause of PD in the current cohort, while no mutations were found in any of the remaining known 
PD genes. It is therefore likely given the differences in the genetic background, and the rich 
genetic diversity within this population, that novel genes may account for the disease in this 
group of patients. Although all 47 patients recruited for the study were self-identified as Black, 
the majority of these patients were from the IsiXhosa Black subpopulation group, and 
originated from the rural Eastern Cape region. It is therefore important that Black PD patients 
from other regions of SA be recruited as these patients may not represent the full spectrum of 
mutations across the different Black ethnic groups in the SA population. There is indeed long 
standing evidence to suggest that genetic background may confer a strong influence on the 
phenotypic expression of disease-causing mutations (Romeo and McKusick, 1994), it can 
therefore be suggested that unique modifier genes may exist within different subpopulations 
groups, and a regionally representative group of Black PD patients (i.e. patients with Sesotho, 
IsiZulu, or Tshivenda, etc. ancestral lineage) would provide an unbiased representation of all 
Black PD patients in the context of the SA population. 
 
The clinical features of PD were not found to be different in this patient group to that of other 
population groups. However, it would be of interest to undertake a larger longitudinal study to 
determine whether in fact there are subtle clinical and neurological differences in Black 
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patients, and differences in their response to treatment. It would also be of interest to compare 
data concerning genotype, disease AAO, disease duration, and clinical and pathological 
features found in patients and controls from similar genetic studies of PD in different African 
countries (Okubadejo et al., 2008; Atadzhanov, 2010; Yonova-Doing, 2012; Cilia et al., 2012). As 
a start, it may be possible to infer the frequency of common-disease causing mutations, or lack 
thereof across several African populations using the collective data of more than 300 Black PD 
patients studied thus far (Pringsheim et al., 2014). 
 
Throughout the course of the present study, the urgent need to expand the study group by 
increasing the number of patients has been consistently reiterated, as this would facilitate a 
better understanding of the unique genetic landscape of the Black population group. 
Additionally, a larger patient group consisting of patients from various SA regions may provide 
more relevant data with regards to the frequency of selective variants in the Black SA PD 
population. Furthermore, the continued search for novel disease-causing genes is warranted, 
as this will in all probability, shed light on yet unknown biological pathways implicated in PD. To 
this end, the Black PD population are a unique and powerful resource for future studies on this 
debilitating disorder. 
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Appendix A: Individual protein domain structures 
Supplementary Material to Chapter 1 
 
Figures 1.5 to 1.10 have been adapted from Corti et al. (2011). 
 
 
 
Figure 1.5 Schematic representation of the α-synuclein protein containing 3 pathogenic point mutations. αSYN 
consists of a NH2 terminus, a central hydrophobic NAC (nonamyloid component) region, and an acidic COOH-
terminal region. Exon numbers above the protein structure indicate the boundaries of each domain.  
 
 
 
Figure 1.6 Schematic representation of the LRRK2 protein. Pathogenic mutations are shown in red and 
mutations that are specific for the Asian population are shown in blue. The amino acid residue numbers beneath 
each domain indicate the estimated domain boundaries. 
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Figure 1.7 Schematic representation of the parkin protein structure. Predicted locations of pathogenic frameshift 
mutations above the transcript (red lines), and protein organizations and missense mutations below the 
transcript (blue lines).Parkin contains an NH2-terminal ubiquitin-like (UBL) domain followed by three RING 
(really interesting new gene) finger domains (RING 0–2) separated by a IBR (in-between-ring) domain in the 
COOH-terminal part. Numbers under the protein line indicate the boundaries of each domain. 
 
 
 
Figure 1.8. Schematic representation of the PINK1 protein. Predicted locations of pathogenic frameshift 
mutations (red lines), and missense mutations (blue lines), and protein organisations. PINK1 consists of a NH2-
terminal mitochondrial targeting signal (MTS) motif, a putative transmembrane (TM) region, and a serine-
threonine kinase. Numbers under the protein line indicate the boundaries of each domain.  
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Figure 1.9 Schematic representation the DJ-1 protein. Predicted locations of pathogenic frameshift mutations 
above the transcript (red lines) and protein organisation and missense mutations below the protein (blue lines). 
DJ-1 consists of a single domain protein, and a critical cysteine residue (Cys106) which can be modified under 
oxidative stress conditions.  
 
 
 
Figure 1.10 Schematic representation of the ATP13A2 transmembrane protein. ATP13A2 consists of 10 
transmembrane domains (M1-10). Functional domains include the A, P1, P2, and N. The positions of different 
mutations are indicated by stars. The position of the in-frame deletion is shown by yellow shading [taken from 
(Podhajska et al., 2012)]. 
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Appendix B: Pedigrees of the Black South African PD patients  
 
 
 
I:1 I:2
II:1
26 Sep 1971
AA0 =30 yrs
42.03/94.69
II:2
11 Apr 1960
AAO= 45 yrs
80.60
II:3 II:4 II:5 II:6 II:7II:8
III:1
age: 16
III:2
age: 5
ZA Family 218 
ZA Family 8 
Stellenbosch University  https://scholar.sun.ac.za
122 
II:1
 1 Jan 1956
age: 57
AAO= 55yrs
10.314
I:1 I:2
II:1
 6 Feb 1965
age: 48
AAO= 45yrs
10.310
I:1 II:2
ZA Family 442 
ZA Family 
439 
ZA Family 
436 
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I:1 I:2
II:1 II:2 II:3 II:5 II:6 II:7 II:8II:4
III:1 III:3 III:4
? - 17 Jul 2012
III:5
 4 Mar 1946 - ?
43.59/74.53
III:7
 1 Jun 1963
43.58/74.54
III:10
74.52
III:11
12 Dec 1959 - ?
74.51
III:6
28 Nov 1958
IV:1 IV:2
III:9
III:8
74.50
III:2
IV:3
V:2V:1
I:1
?
I:2
II:1
22 Aug 1950
52.23
II:2
 8 Jul 1958
III:1
33
III:2
23
III:3
21
II:1
 2 Feb 1956
AAO= 42 yrs
55.52
I:1 II:2
II:3 II:4II:5II:6 II:7
III:1 III:2 III:3III:4
ZA Family 15 ZA Family 22 
ZA Family 
434 
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.   
II:1
 6 Jan 1936
AA0= 49 yrs
10.308
I:1 II:2
II:1
28 Jul 1958
42.56
?
I:1 I:2
ZA Family 25 ZA Family 14 ZA Family 37 
ZA Family 
435 ZA Family 434 
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II:1
21 Nov 1963
age : 50
AAO= 44 yrs
10.307
I:1 I:2
II:1
19 Dec 1944
AAO= 59 yrs
63.73
?
I:1
?
I:2
II:2
III:1
II:1
22 Jul 1922
AAO= 74 yrs
63.42
?
I:1
?
I:2
II:1
 6 Jun 1949
AAO= 55 yrs
61.81
?
I:1
?
II:2
I:1 I:2
II:1
28 Dec 1963
AAO= 40yrs
55.65
II:2 II:3 II:4 II:5 II:6 II:7
ZA Family 
433 
ZA Family 
53 
ZA Family 
48 
ZA Family 
46 
ZA Family 38 
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Appendix C: Primers designed for mutation screening 
Supplementary Material to Chapter 2 
Table 2.2. Primers used and PCR conditions for amplification, and sequencing of PARK2, DJ-1, LRRK2, VPS35, and EIF4G1. 
Gene Exonic 
region 
Primer Sequence (5´-3´) Size of PCR 
fragment (bp) 
Annealing 
temp. (0C) 
PCR Conditions 
PARK2 Exon 1 For: gaa cta cga ctc cca gca g 
Rev: ccc gtc att gac agt tgg 
300 58 2.5 mM MgCl2  
5.0 M Betaine  
PARK2 Exon 2 For: cac cat tta agg gct tcg ag 
Rev: tca ggc atg aat gtc aga ttg 
313 55 1.5 mM MgCl2  
PARK2 Exon 3 For: tct cgc att tca tgt ttg aca 
Rev: gca gac tgc act aaa caa aca 
364 55 1.5 mM MgCl2 
PARK2 Exon 4 For: gct ttt aaa gag ttt ctt gtc 
Rev: ttt ctt ttc aaa gac ggg tga 
299 55 1.5mM MgCl2 
PARK2 Exon 5 For: gga aac atg tct taa gga gt 
Rev: ttc ctg gca aac agt gaa ga 
223 60 2.5mM MgCl2  
5% Formamide 
PARK2 Exon 6 For: cca aag aga ttg ttt act gtg 
Rev: ggg gga gtg atg cta ttt tt 
276 55 2.5 mM MgCl2 
5% Formamide 
PARK2 Exon 7 For: cct cca gga tta cag aaa ttg 
Rev: gtt ctt ctg ttc ttc att agc 
280 55 1.5 mM MgCl2  
VPS35 Exon 15 
D620N 
mutation 
For: agg ctg cag aag tct cac agg a 
Rev: agg gca ggg gga cag tga aga 
257 55 1.5 mM MgCl2 
EIF4G1 Exon 23 
R1205H 
mutation 
For: aca agg ccc aac agt tgc tca g 
Rev: agg gac ttt tca gtc ttc cca gca 
243 56 1.5 mM MgCl2 
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Table 2.2. Primers used and PCR conditions for amplification, and sequencing of PARK2, DJ-1, LRRK2, VPS35, and EIF4G1. Continued 
Gene Exonic region Primer Sequence (5´-3´) Size of PCR fragment 
(bp) 
Annealing 
temp. (0C) 
PCR Conditions 
PARK2 Exon 8 For: ggc aac act ggc agt tga ta 
Rev: ggg gag ccc aaa ctg tct 
232 55 1.5 mM MgCl2
PARK2 Exon 9 For: tcc cat gca ctg tag ctc ct  
Rev: cca gcc cat gtg caa aag 
297 55 1.5 mM MgCl2
PARK2 Exon 10 For: caa gcc aga gga atg aat at 
Rev: gga act ctc cat gac ctc ca 
272 55 1.5 mM MgCl2
PARK2 Exon 11 For: ccg acg tac agg gaa cat aaa 
Rev: ggc acc ttc aga cag cat ct 
300 55 1.5 mM MgCl2
PARK2 Exon 12 (set A) For: tct agg cta gcg tgc tgg tt 
Rev: gcg tgt gtg tgt gtg ttt ga  
296 55 1.5  mM MgCl2 
SNCA Exon 2 For: ccc cca agt tct cat tca a 
Rev: ccc atc act cat gaa caa gc 
235 55 2.5 mM MgCl2 
SNCA Exon 3 For: ttt aag gct agc ttg aga ct 
Rev: cca cac taa tca cta gat ac 
146 40 2.5 mM MgCl2 
LRRK2 Exon 31 For: tga atg tca cgg aaa gca aa 
Rev: ttc tca act gcc tag aaa tgt 
cag 
173 55 1.5 mM MgCl2 
LRRK2 Exon 41 For: gca cag aat ttt tga tgc ttg 
Rev: gga tgg ata acc act gac ctc 
313 55 1.5 mM MgCl2 
DJ-1 Exon 1 For: cac cca ggg ctg tcc agc ta 
Rev: caa cgc tga agc gtc cag aa 
238 55 1.5 mM MgCl2 
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Table 2.2. Primers used and PCR conditions for amplification, and sequencing of PARK2, DJ-1, LRRK2, VPS35, and EIF4G1. Continued 
Gene Exonic region Primer Sequence (5´-3´) Size of PCR fragment 
(bp 
Annealing 
temp. (0C) 
PCR Conditions 
DJ-1 Exon 2 For: ctc tgc ttg aaa atg ctc ct 
Rev: aat gtt ttt gga ttt taa a 
220 55 1.5 mM MgCl2 
DJ-1 Exon 3 For: cag ggt gag acc cca tct ctc t 
Rev: gga gtt att cct tca tat ggc ttc 
tttg tt 
256 55 1.5 mM MgCl2 
DJ-1 Exon 4 For: tgt caa ttt aat gca cag ttg a 
Rev: ttc aaa tat ttc ggg agg agg 
117 55 1.5 mM MgCl2 
DJ-1 Exon 5 For: agg tca gag agc ttg tgg ttt 
Rev:ggt agc ctt tca ttc gat ggt 
152 55 1.5 mM MgCl2 
DJ-1 Exon 6 For: cca ggc act att gcg att tt 
Rev: ttg aga tgg agt ctc gct cc 
243 55 1.5 mM MgCl2 
DJ-1 Exon 7 For: cgt ctt tct cgt cac ata gcc 
Rev: aat gtg ttc aga agt cgc tgt cct 
177 57 1.5 mM MgCl2 
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Supplementary Material to Chapter 2 continued. 
 
Table 2.3 Primers used for amplification of GBA. 
Exonic regions Primer Sequence (5´-3´) 
 Forward                                                              Reverse 
Exons 1-5 CCTAAAGTTGTCACCCATAC AGCAGACCTACCCTACAGTTT 
Exons 5-7 GACCTCAAATGATATACCTG AGTTTGGGAGCCAGTCATTT 
Exons 8-11 TGTGTGCAAGGTCCAGGATCAG ACCACCTAGAGGGGAAAGTG 
Individual primer sequences 
Exons and flanking 
regions  
Forward   Reverse 
Exon 1 CCTAGTGCCTATAGCTAAGG CATTCATTAAATTCCAGTGCC 
Exon 2 GTCCTAATGAATGTGGGAGACC TTGAGCACCTACTAAAAGTC 
Exon 3 GCAAGGCAGGTCTCAAACTC GGAAACTCCATGGTGATCAC 
Exon 4 AATCACACGGGCACAGGTAA GCAGAGTGAGATTCTGCCTC 
Exon 5 GCAAGTGATAAGCAGAGTCC AGCAGACCTACCCTACAGTTT 
Exon 6 TGAACCGGATGCACTGGTTG GGAAGTGGAACTAGGTTGAGG 
Exon 7 TTGGCCGGATCATTCATGAC CTCTAAGTTTGGGAGCCAGTC 
Exon 8 GCTTCTGTCAGTCTTTGGTG CTGGACAGGAAGGGCTTCT 
Exon 9 CTCGTGGTGTAGAGTGATGTAAG GCTCCCTCGTGGTGTAGAGT 
Exon 10 &11 GTGGGCTGAAGACAGCGTTGG GAGGCACATCCTTAGAGGAG 
 
The primer sequences were custom designed to avoid amplifying and sequencing the neighboring 
pseudogene. 
Fragment 1 (Exons 1-5) = 2972 bp, fragment 2 (Exons 5-7) = 2049 bp, and fragment 3 (Exons -11) = 
1682 bp 
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Table 2.4 Customised touch down (TD) PCR conditions used for each GBA fragment. 
Fragment 1 (2972pb) Fragment 2 (2049pb) Fragment 3 (1682pb) 
TD 64-54 TD 64-54 
Unique 
program 
96°C    5 min 96°C    5 min 94°C  5 min 
96°C    30 sec 96°C    30 sec 94°C  45 sec 
64°C    30 sec 2 cycles 64°C    30 sec 2 cycles 62-60°C  45 sec 20 cycles 
72°C    3 min 72°C    2 min 72°C  3 min 
96°C    30 sec 96°C    30 sec 94°C  45 sec 
63°C    30 sec 2 cycles 63°C    30 sec 2 cycles 60°C  45 sec 18 cycles 
72°C    3 min 72°C    2 min 72°C  3 min 
96°C    30 sec 96°C    30 sec 72°C  7 min 
62°C    30 sec 2 cycles 62°C    30 sec 2 cycles 
72°C    3 min 72°C    2 min 
96°C    30 sec 96°C    30 sec 
61°C    30 sec 2 cycles 61°C    30 sec 2 cycles 
72°C    3 min 72°C    2 min 
96°C    30 sec 96°C    30 sec 
60°C    30 sec 2 cycles 60°C    30 sec 2 cycles 
72°C    3 min 72°C    2 min 
96°C    30 sec 96°C    30 sec 
59°C    30 sec 2 cycles 59°C    30 sec 2 cycles 
72°C    3 min 72°C    2 min 
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Table 2.4 Customised touch down (TD) PCR conditions used for each GBA fragment. Continued 
Fragment 1 (2972pb) Fragment 2 (2049pb) 
96°C    30 sec 96°C    30 sec 
58°C    30 sec 2 cycles 58°C    30 sec 2 cycles 
72°C    3 min 72°C    2 min 
96°C    30 sec 96°C    30 sec 
57°C    30 sec 2 cycles 57°C    30 sec 2 cycles 
72°C    3 min 72°C    2 min 
96°C    30 sec 96°C    30 sec 
56°C    30 sec 2 cycles 56°C    30 sec 2 cycles 
72°C    3 min 72°C    2 min 
96°C    30 sec 96°C    30 sec 
55°C    30 sec 2 cycles 55°C    30 sec 2 cycles 
72°C    3 min 72°C    2 min 
96°C    30 sec 96°C    30 sec 
54°C    30 sec 25 cycles 54°C    30 sec 25 cycles 
72°C    3 min 72°C    2 min 
72°C    10 min 72°C    10 min 
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Appendix D: List of genes included on the customized target-capture panel 
Table 2.5 List of genes included in the neurodegeneration screening panel. 
Disease/ associated pathway Gene 
ACCPN SLC12A6 
AD APOE 
AD APP 
AD BACE1 
AD BIN1 
AD CLU 
AD GAB2 
AD PICALM 
AD PSEN1 
AD PSEN2 
AD3 SERPINA3 
ALS FUS 
ALS SOD1 
ALS SPG11 
ALS TARDBP 
ALS/FTD C9orf72 
ALS12 OPTN 
ALS2 ALS2 
ALS4 SETX 
ALS8 VAPB 
ALS9 ANG 
bipolar NR2E1 
Cadasil NOTCH3 
CCFDN CTDP1 
CJD PRNP 
CMT1 ARHGEF10 
CMT1/2 MPZ 
CMT1/2 NEFL 
CMT1A PMP22 
CMT1C LITAF 
CMT1D EGR2 
CMT20 DYNC1H1 
CMT2A2 MFN2 
CMT2B RAB7A 
CMT2B1 LMNA 
CMT2D GARS 
CMT2F HSPB1 
CMT2K/4A GDAP1 
CMT2L HSPB8 
CMT2M DNM2 
CMT4B1 MTMR2 
CMT4B2 SBF2 
CMT4C SH3TC2 
CMT4D NDRG1 
CMT4F PRX 
CMT4H FGD4 
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Table 2.5 List of genes included in the neurodegeneration screening panel. Continued. 
Disease/ associated pathway Gene 
CMTDIC YARS 
CMTX1 GJB1 
CMTX5 PRPS1 
dHMN V BSCL2 
dSMA1 IGHMBP2 
Dyskinesia PRRT2 
Dystonia ACTB 
Dystonia ATP1A3 
Dystonia DRD2 
Dystonia GCDH 
Dystonia GCH1 
Dystonia MR1 
Dystonia PRKRA 
Dystonia SGCE 
Dystonia SLC2A1 
Dystonia SLC6A3 
Dystonia TAF1 
Dystonia THAP1 
Dystonia TIMM8A 
Dystonia TOR1A 
FTD GRN 
FTD MAPT 
FTLD CHMP2B 
FTLD/FTD VCP 
GAN1 GAN 
HNA SEPT9 
HSAN1A SPTLC1 
HSAN2A WNK1 
HSAN3 IKBKAP 
HSAN4 NTRK1 
HSAN5 NGF 
Kufor-Rakeb ATP13A2 
NBIA1 C19orf12 
NBIA1 PANK2 
NBIA2A PLA2G6 
NBIA3 FTL 
PARK16 RAB7L1 
CMT4J FIG4 
PD BST1 
PD EIF4G1 
PD GABP1 
PD GAK 
PD GBA 
PD GPNMB 
PD HLA-DRB5 
PD HSP40 
PD LRRK2 
PD MAOA 
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Table 2.5 List of genes included in the neurodegeneration screening panel. Continued. 
Disease/ associated pathway Gene 
PD MAOB 
PD MCCC1 
PD PARK2 
PD PARK7 
PD PINK1 
PD PM20D1 
PD RAB25 
PD SETD1A 
PD SNCA 
PD SNCB 
PD SNCG 
PD SPR 
PD STK39 
PD TH 
PD UCHL1 
PD VPS35 
PD - ET LINGO1 
PERRY DCTN1 
PKPS FBXO7 
PSP STX6 
Schizophrenia COMT 
Schizophrenia DTNBP1 
SCZD2 FXYD6 
SCZD4 PRODH 
SCZD9 DISC1 
SMA SMN1 
SMA SMN2 
Wilson's ATP7B 
WS4C SOX10 
Dopamine pathway DRD1 
Dopamine pathway DRD3 
Dopamine pathway DRD4 
Dopamine pathway DRD5 
Dopamine pathway SLC18A2 
EIF complex EIF4G3 
EIF complex PABPC1 
EIF complex PABPC1L 
Retromer complex SNX1 
Retromer complex SNX2 
Retromer complex SNX32 
Retromer complex SNX5 
Retromer complex SNX6 
Retromer complex VPS26A 
Retromer complex VPS26B 
Retromer complex VPS29 
Retromer complex VPS54 
Retromer complex WASH 
Vesicle dynamics DNM1 
Vesicle dynamics DNM3 
Vesicle dynamics EHD1 
Vesicle dynamics EHD2 
Vesicle dynamics EHD3 
Vesicle dynamics FCHO1 
Vesicle dynamics FCHO2 
Vesicle dynamics HGS 
Vesicle dynamics HSPA8 
Vesicle dynamics RAC1 
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Table 2.5 List of genes included in the neurodegeneration screening panel. Continued. 
Disease/ associated pathway Gene 
Vesicle dynamics SH3GL1 
Vesicle dynamics SH3GL2 
Vesicle dynamics SH3GL3 
Vesicle dynamics SYNJ1 
Vesicle dynamics SYNJ2 
Vesicle dynamics DNAJC5 
Vesicle dynamics SGTA 
Vesicle dynamics SH3BP4 
Vesicle dynamics SNAP25 
Vesicle dynamics STX10 
Vesicle dynamics STX16 
Vesicle dynamics VAMP1 
Vesicle dynamics VAMP2 
Vesicle dynamics VAMP4 
Vesicle dynamics VAMP7 
Vesicle dynamics VAMP8 
Vesicle dynamics VTI1A 
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Appendix E: Primers Designed for Validation of NGS Results 
Table 2.6 Individual primer sequences used for confirmation of NGS results. 
Gene Exonic region Primer Sequence (5´-3´) Size of PCR fragment (bp) Annealing temp. (0C) PCR Conditions 
PARK2 Exon 8 For: CAC TGG CAG ATA GCA GAT GTA G 
Rev: GCT GTC CCA ACT CCT TGA TTA 
277 55 1.5 mM MgCl2 
GBA Exon 12 For: CTG TTG TGG TCG TGC TAA AC 
Rev: CAG GTA GGT GTG AAT GGA GTA G 
207 58 1.5 mM MgCl2 
DNAJC13 Exon 44 For: TGT CTG CAT TGA TTA GGT TCC A 
Rev: GGT GTA GTC ACA TAC CTG GAT TG 
209 55 1.5 mM MgCl2 
DCTN1 Exon 8 For: CTT TCT TTC TGG TCT GCC TCT AC 
Rev: TGG GTG TCT TGA TTC TCC TTT AC 
269 55 1.5 mM MgCl2 
ATP13A2 Exon 22 For: AGC TGT ACC TCA CCC AGT 
Rev: TGA GGA AGG AGA CAG AGC A 
278 56 1.5 mM MgCl2 
LRRK2 Exon 7 For: TGC TGC CAT CTA TTT ACA GTC TAT 
Rev: GAG CAA ACA GCA ACT CAC TTC 
223 55 1.5 mM MgCl2 
LRRK2 Exon 16 For: GCT GGT GAC TGG ATG TCT TTA 
Rev: CGC ACA AGT TCC CAA ATT CTT 
256 55 1.5 mM MgCl2 
LRRK2 Exon 36 For: CAC TTG TGT TGT GTG CAG TAG 
Rev: CTG TCG CAA AGC TTT AAG GTA A 
314 55 1.5 mM MgCl2 
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Table 2.6 Individual primer sequences used for confirmation of NGS results. Continued 
Gene Exonic region Primer Sequence (5´-3´) Size of PCR fragment (bp) Annealing temp. (0C) PCR Conditions 
LRRK2 Exon 49 For: TGG TTC TAG GGA GGT AAT GGT 
Rev: CCA TCC ATA TGA CAC TGG AAA GT 
334 55 1.5 mM MgCl2 
MAPT Exon 11 For: GTG GTG AGC CTG GGA ATG 
Rev: ATT CTT CAG GTC TGG CAT GG 
337 55 1.5 mM MgCl2 
PSEN1 Exon 5 For: GAG GTG GTA ATG TGG TTG GT 
Rev: CCA TAA GAA GAA CAG GGT GGA A 
258 55 1.5 mM MgCl2 
PSEN1 Exon 7 For: GTT TGG GAG CCA TCA CAT TAT TC 
Rev: CCC AGC CGA AAT CTT CAA ATG 
268 55 1.5 mM MgCl2 
PSEN2 Exon 6 For: GCA GGT CCA GAA TCA CTC AA 
Rev: AGA GCA CCA CCA AGA AGA TG 
208 55 1.5 mM MgCl2 
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Appendix F: Tolerance scores used to make in silico protein functional predictions 
Table 2.7 Distribution of prediction scores used by SIFT, PolyPhen and MutationTaster [taken from (Cargill et 
al., 1999; Xi et al., 2004)]. 
PolyPhen 
score 
Potential 
impact 
SIFT score Potential 
impact 
MutationTaster 
score 
Potential 
impact 
>2.00 Damaging 0.00 Deleterious 0.5 -1.00 Disease-
causing 
1.99– 1.75 Probably 
damaging 
0.01– 0.05 Deleterious 0.00 - 0.4 Polymorphism 
1.74– 1.50 Probably 
damaging 
0.051– 0.10 intolerant 
1.49– 1.25 Probably 
damaging 
0.101– 0.20 Borderline 
1.24– 1.00 Borderline 0.201– 0.50 Tolerant 
0.99– 0.50 Benign 0.501– 0.99 Tolerant 
0.49– 0.01 Benign 1.00 Tolerant 
0.00 Benign 
The SIFT, PolyPhen and MutationTaster predictive scores, as outlined in Table 2.7, were used to classify the 
13 confirmed sequence variants generated using NGS. Although these algorithms are not 100% accurate, they 
can be effectively used to further reduce the number of variants for further investigation on a function level. 
Table S.3 Primers used for confirmation of NGS results. Continued.
Gen
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Appendix G: Phenol-chloroform DNA extraction method 
Reagents: 
▪ Cell lysis buffer (store at 4˚C for 6-8 weeks)
 109.5g Sucrose,
 10ml of 1M Tris-HCl pH 7.4,
 5ml of 1M MgCl2,
 10ml Triton X,
 Distilled H2O to a final volume of 1L
▪ Sodium-EDTA, pH8
▪ 10% SDS
▪ Proteinase K (10 mg/mL), -20°C
▪ Sterile, Distilled H2O
▪ 3M Sodium Acetate (pH 6 with acetic acid)
▪ Phenol: Chloroform, (1:1, v/v) pH 8, 4°C
▪ Chloroform:Octonal (24:1 v/v)
▪ Ice-cold 96% Ethanol, -20°C
▪ 70% Ethanol (RT)
Extraction procedure: 
1. Pool the blood (at least ~10mL in total) into a 50mL centrifuge tube. Fill to 45mL mark with
ice-cold cell lysis buffer – invert several times to mix & incubate on ice for 10 minutes. Invert
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the tube several times. Pellet cells at 3000rpm for 10 minutes at 4˚C. Pour off the 
supernatant.  
2. Repeat the wash step with cell lysis buffer once more – pellet should be light pink in colour.
3. Add 900μL of Sodium-EDTA and 100μL 10 % SDS to each pellet. May be stored at this
stage at -20˚C. 
4. Add 100μL Proteinase K to each 50 mL tube. Mix gently by vortexing. Incubate at 37˚C
overnight. 
5. Add 2mL of distilled H2O and 500μL of Sodium Acetate to each 50 mL tube. Mix gently by
shaking.
6. Add 2.5mL Phenol-Chloroform to each 50 mL and close the lids tightly. In the cold room,
place the tubes on a shaker and shake at 140 rpm for 10 minutes.
7. Pour the mixture into a 10mL Corex glass tube and spin at 8000 rpm for 12 minutes at 4˚C.
Use the Sorval centrifuge with the SS34 head.
8. Using a plastic Pasteur pipette, gently transfer the upper aqueous phase to a clean Corex
glass tube without disturbing the interphase.
9. Add 2.5 mL Chloroform: Octonal to each Corex glass tube containing the aqueous phase.
Seal with rubber tops and mix slowly by inversion until the mixture turns milky.
10. Remove the rubber tops and spin at 8000 rpm for 12 minutes at 4˚C in the Sorval centrifuge.
11. Transfer the upper aqueous phase to 15 mL plastic Greiner tubes. To precipitate the DNA,
add 5-7 mL of ice-cold 96% ethanol. Seal the tube with plastic cap and mix gently by inversion
until the DNA precipitates out of solution.
a. The protocol may be ‘paused’ at this point, prior to the addition of alcohol.
12. With the aid of a pipette, transfer the DNA precipitate to a clean 1.5 mL Eppendorf tube.
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13. Add 1 mL of 70% Ethanol to the Eppendorf tube, invert several times to wash the DNA, and
spin at 14000 rpm for 3 minutes. Pour off supernatant carefully so as not to disturb the pellet.
Repeat this step.
14. Air-dry at room temperature for ~10 minutes.
15. Resuspend the dried DNA in 300-500μL TE solution and incubate overnight at 37˚C, or for
10 minutes at 65˚C.
16. Ensure the Eppendorf tubes are tightly sealed and place into a 50 mL tube. Place tubes on
rotating wheel in cold-room and mix for a minimum of 3 days at 30 rpm.
17. Read optical density at 260 nm and 280 nm.
Store at 4˚C for further manipulation, or at -20˚C for long-term storage. 
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